Track market-moving stories before they get noisy

By You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Two of the new bubbly drinks from Starbucks. Starbucks Starbucks CEO Brian Niccol is ready for some fizz.

The company is testing a carbonated version of its Refreshers, which are iced juice and tea drinks often mixed with fruit pieces, that have become one of Starbucks' biggest beverage businesses since launching in 2012.

"I'm really excited that we're getting ready to go test sparkling. We're calling it Spritzers," he told investors on the company's third quarter earnings call Wednesday. The company delivered net sales of $9.3 billion for the period, with global comparable sales growth of 7.9%.

Of course, sparkling drinks have been a fast food chain staple since the beginning of the industry. After all, what's a Big Mac without a Coke?

But lest you think the Seattle coffee giant is apparently just now getting the memo on soda, Niccol says his baristas are taking a distinctive approach to bubbles.

"Our team does a great job on getting to the delicious flavors that are relevant for the customer. So it's been a really strong platform for us, and over the last quarter, really continued to perform," he said.

Starting this week, the company said it was testing out the spritz concept at about 100 stores in Austin, San Antonio, and St. Louis.

This is not a Coke. It's a Sparkling Cold Brew Sour Spritz  Starbucks The category expansion for Starbucks follows new Energy refreshers and Blended refreshers options rolled out earlier this summer. It also comes after nearly two years of a Niccol-led focus on fundamentals, like craft coffee and quicker, friendlier service.

One goal of the change is to increase business during the afternoon, once the morning coffee rush has subsided. The non-coffee flavors also help attract younger customers to the brand.

The sparkling flavor lineup includes a coffee and citrus combo, a peach and passion fruit tea, and a strawberry matcha mashup.

"It's been a platform, frankly, that we kind of got a little complacent on in the past, and now we are reinvigorating," Niccol said on the earnings call. "Whether it's fully decaffeinated or whether it's fully boosted, those are the different occasions that people want Refreshers, whether it's in the morning or the afternoon, and whether you're young or old, the platform is resonating."

Read next

Dominick Reuter You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Dominick Reuter is a senior retail reporter for Business Insider, primarily covering Walmart, Target, and Costco. His stories tend to focus on issues and trends that affect employees and customers.Prior to joining BI in 2019, Dominick worked for more than a decade as an independent photojournalist covering a wide range of stories for global wire services and newspapers, including Reuters, the Wall Street Journal, and Agence France-Presse.Dominick studied photojournalism at Boston University and later earned a Masters in business and economics journalism from Columbia University.If you're an employee or customer with a story to share, please contact me via email or text/call/Signal at 646-768-4750.

Fast Food Drinks Starbucks More

@Shopify has added $USDC payment support to its core payments stack, with @Arbitrum among the supported networks. The integration allows over 480 compatible digital wallets to execute retail transactions directly through Shopify Payments, positioning stablecoins as a practical alternative to traditional card networks for merchants worldwide.

How It Works at Checkout Shopify has wired USDC directly into its payments stack, allowing merchants to accept digital dollars at checkout without adding new providers or changing existing workflows. The feature sits inside Shopify Payments, meaning merchants can enable it alongside credit cards and other payment options.

Shopify Payments accepts $USDC on five networks: Base, Ethereum L1, Optimism, Polygon, and Arbitrum, with access through 480-plus supported crypto wallets and no gas fees charged to the buyer. Crucially, no foreign exchange fees apply either, removing two of the most common friction points for cross-border commerce.

Customers can pay with USDC on Ethereum, Base, or other chains, and funds bridge automatically, so the merchant does not need to think about which network the buyer used.

Settlement Options and Merchant Flexibility On the back end, merchants can choose whether to receive funds in traditional fiat payouts or settle in USDC on-chain. Shopify states that USDC payments convert to local currency by default, with no foreign exchange or multi-currency fees, and deposit to the connected bank account.

The integration is built in partnership with Stripe and Coinbase for wallet connectivity and transaction processing, with settlement occurring on Base and support for USDT planned.

The move reflects a broader shift in commerce infrastructure. Stablecoin payments reached $1.1 trillion in transaction volume in 2024, with Visa and Allium Labs confirming that stablecoins processed 2.5 times Visa's adjusted transfer volume that same year. For merchants processing high volumes of cross-border transactions, the economics are hard to ignore.

PYMNTS: Shopify Signals Stablecoin Preferences With USDC Integration
Digital Applied: Shopify Spring 2026 Checkout and Payments Updates
Shopifreaks: Shopify Adds USDC Stablecoin to Its Core Payments Stack

Blockchain

30 July 2026 | 20:11 Open USD will launch on Ethereum from its first day of operation as part of a broader multichain rollout that also includes Solana, Base, Stellar and Polygon.

The July 30 announcement from Ethereum Institutional confirms the network’s inclusion and highlights its role in the stablecoin’s business-focused settlement infrastructure.

As we previously reported, more than 140 companies have joined Open Standard, including Visa, Mastercard, Stripe, BlackRock and BNY. Under the proposed model, most reserve income would be shared with businesses that distribute and use the stablecoin instead of remaining entirely with a single issuer.

Why Ethereum Matters to Open USD Ethereum offers payment companies a shared settlement network without placing the underlying ledger under the control of any one participant.

That matters when companies such as Visa, Mastercard and Stripe are expected to use the same infrastructure. Each can verify the asset and its settlement rules without relying on a private system operated by a direct competitor.

Ethereum also brings established liquidity, mature infrastructure and familiarity among institutional market participants. Other supported networks can then handle transfers where lower fees or faster execution matter more.

Breaking: Open USD will launch on @ethereum on day one.

Over 140 businesses, including Visa, Mastercard, Stripe, BlackRock and BNY. All reserve earnings flow to the partners that grow it.

A shared asset needs neutral ground.

We’re excited to be working with @openstandard on… pic.twitter.com/WF3ure6Dhb

— Ethereum Institutional (@ethereuminsti) July 30, 2026

Open USD Is Being Built for Business Use Open USD is being positioned mainly for corporate settlement, cross-border treasury activity, payment processors and institutional liquidity rather than retail trading.

Consumers may therefore use it without interacting with the stablecoin directly. A merchant, payroll platform or remittance service could settle through Open USD behind the scenes while customers continue paying and receiving funds in local currency.

Its business model is also different from those of USDT and USDC. Participating companies that help distribute Open USD are expected to receive a share of the reserve earnings. That could give exchanges, payment firms and fintech platforms a financial reason to integrate it, although ordinary token holders are not automatically entitled to yield.

Ethereum Fees Will Matter Most to Businesses Ethereum transaction costs remain a practical consideration, especially for treasury desks, payment processors and other companies handling large volumes.

These firms can reduce costs by batching transfers, settling larger amounts less frequently or routing smaller transactions through cheaper supported networks. Ethereum is more likely to serve high-value settlement and liquidity needs than individual purchases at checkout.

Its inclusion from day one gives Open USD access to a major institutional market. Support for several networks broadens the stablecoin’s potential use across payments, trading and treasury operations without requiring all activity to pass through Ethereum mainnet.

Author

Alex is Editor-in-Chief of Coindoo and co-founder of Millennial Media Group, with nearly a decade of experience covering financial markets - crypto first, then everything else. It started in 2016 with Bitcoin. Like most people at the time, he didn't fully understand it - so he kept digging. Blockchain, tokenomics, the projects, the cycles. That curiosity never stopped, and eventually pulled him into traditional markets too: equities, commodities, macro. Not because he left crypto behind, but because you can't properly understand one without the other. What drives him is straightforward: he wants to know why something is happening, not just that it's happening. Most market coverage stops at the headline - price up, price down, here's a chart. Alex finds that kind of reporting actively unhelpful. If you walk away from an article without understanding the mechanism behind the move, what did you actually learn? He holds a degree in Tourism from New Bulgarian University - not the most obvious path into financial markets, but markets have a way of pulling in people who are simply too curious to stay out. He has authored over 200 in-depth analyses and more than 10,000 articles across crypto and traditional finance. He still thinks every day in markets teaches him something new. That's probably why he hasn't stopped.

Key Takeaways Palantir will report Q2 earnings on Aug. 3, with earnings seen rising 118.8% and revenues climbing 80%.Government revenues are projected to rise 65.7%, while Commercial revenues are expected to jump 98%.PLTR trades far above industry valuation multiples despite a 22% share-price decline over the past year. Palantir Technologies Inc. (PLTR - Free Report) will report its second-quarter 2026 results on Aug. 3, after the bell.

The Zacks Consensus Estimate for earnings in the to-be-reported quarter stands at 35 cents, indicating 118.8% growth from the year-ago reported quarter. The consensus estimate for total revenues stands at $1.81 billion, indicating 80% year-over-year growth. There have been no changes or revisions to analyst estimates lately.

                                                                Image Source: Zacks Investment Research

The company has a strong history of earnings surprises. Earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and matched it once, with an average earnings surprise of 11.6%.

PLTR’s Lesser Chance of Q2 Earnings BeatOur proven model doesn’t conclusively predict an earnings beat for PLTR this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.

PLTR has an Earnings ESP of 0.00% and a Zacks Rank #2.

You can see the complete list of today’s Zacks #1 Rank stocks here.

PLTR’s All-Round Healthy Business Should be the Driver in Q2We expect a significant year-over-year improvement in the company’s top line in the to-be-reported quarter, driven by healthy business from existing and new customers, strengthening both the Government and Commercial segments.

The consensus estimate for Government revenues is pegged at $916.2 million, indicating 65.7% year-over-year growth. The consensus mark for Commercial revenues is pegged at $892.1 million, suggesting 98% year-over-year growth.

PLTR Stock Experiencing PullbackPalantir shares have declined 22% over the past year and 15% over the past three months. This performance clearly indicates a pullback in the stock.

                                                              Image Source: Zacks Investment Research

Based on trailing 12-month EV-to-EBITDA, PLTR is currently trading at 162.72X, way above the industry’s 10.66X. If we look at the forward 12-month Price/Earnings ratio, the company’s shares are currently trading at 67.27X forward earnings, well above the industry’s 26.51X.

Investment ConsiderationsPalantir continues to distinguish itself through rapid commercial adoption, expanding customer relationships, improving profitability, and disciplined execution. The company's Artificial Intelligence Platform is gaining traction across enterprises, while larger contracts and a growing customer base provide visibility into sustained long-term growth. At the same time, exceptional operating efficiency demonstrates that Palantir is scaling its business without compromising profitability. So, the recent share-price weakness appears to present a compelling opportunity for long-term investors. Despite near-term valuation concerns, Palantir's strengthening fundamentals support a Buy recommendation for investors seeking exposure to one of the software industry's leading AI growth stories.

Peer ViewPLTR’s competitive strengths are reflected in its financial performance. The company delivered 85% revenue growth in the first quarter of 2026, including an exceptional 133% increase in U.S. commercial revenues, while generating a 60% adjusted operating margin and a 53% GAAP net margin. Even leading AI software companies like Datadog (DDOG - Free Report) and Snowflake (SNOW - Free Report) struggle to match this combination of rapid expansion and profitability.

While DDOG and SNOW continue to benefit from AI demand, their growth rates remain significantly lower. By combining a durable software foundation with industry-specific expertise and superior execution, Palantir continues to separate itself from DDOG, SNOW and traditional enterprise software competitors.

Repatha ist der einzige PCSK9-Hemmer, der in einer klinischen Phase-3-Studie nachweislich das Risiko eines ersten Herzinfarkts und Schlaganfalls signifikant senkt und damit neue Maßstäbe bei der Senkung kardiovaskulärer Risiken setzt.

Die Empfehlung stützt sich auf die bahnbrechende globale Phase-3-Studie „VESALIUS-Cardiovascular" mit mehr als 12.000 Patientinnen und Patienten.

, /PRNewswire/ -- Amgen (NASDAQ: AMGN) gab heute bekannt, dass der Ausschuss für Humanarzneimittel (Committee for Medicinal Products for Human Use, CHMP) der Europäischen Arzneimittelagentur (EMA) eine positive Stellungnahme zu Repatha® (Evolocumab) für Erwachsene mit nachgewiesener oder hohem Risiko einer atherosklerotischen Herz-Kreislauf-Erkrankung zur Senkung des kardiovaskulären Risikos durch Senkung des LDL-C-Spiegels als Ergänzung zur Korrektur anderer Risikofaktoren abgegeben hat. Die Empfehlung stützt sich auf die Ergebnisse der Phase-3-Studie VESALIUS-CV, die gezeigt hat, dass Repatha das Risiko für schwerwiegende unerwünschte kardiovaskuläre Ereignisse (Major Adverse Cardiovascular Events, MACE) bei Erwachsenen mit hohem Risiko, die zuvor weder einen Herzinfarkt noch einen Schlaganfall erlitten hatten, signifikant senkte, wenn es zusätzlich zu Statinen oder anderen LDL-C-senkenden Therapien verabreicht wurde.

„In Europa besteht nach wie vor ein erheblicher ungedeckter Bedarf, da viele Patientinnen und Patienten mit hohem kardiovaskulärem Risiko trotz der verfügbaren lipidsenkenden Therapien nicht in der Lage sind, die empfohlenen LDL-C-Werte zu erreichen", sagte Dr. med. Paul Burton, Ph.D., Chief Medical Officer bei Amgen. „Die positive Stellungnahme des CHMP spiegelt die Aussagekraft der klinischen Daten zu Repatha wider und bringt uns einen Schritt näher, wenn es darum geht, Repatha für mehr Patientinnen und Patienten verfügbar zu machen, die davon profitieren könnten." Repatha ist der einzige PCSK9-Hemmer, der in einer klinischen Phase-3-Studie nachweislich das Risiko eines ersten schwerwiegenden unerwünschten kardiovaskulären Ereignisses senkt. Sollte die Europäische Kommission dieser erweiterten Indikation zustimmen, könnte dies die kardiovaskuläre Versorgung geeigneter Patientinnen und Patienten in Europa grundlegend verändern."

Herz-Kreislauf-Erkrankungen sind weltweit die häufigste Todesursache.1 Aktuelle Forschungsergebnisse zeigen, dass mehr als 99 % der Menschen, bei denen erstmals ein kardiovaskuläres Ereignis auftritt, mindestens einen traditionellen Risikofaktor aufweisen, darunter einen hohen LDL-C-Spiegel, der zu den am besten beeinflussbaren Risikofaktoren für einen Herzinfarkt oder Schlaganfall zählt.2 Während die Leitlinien der Europäischen Gesellschaft für Kardiologie (European Society of Cardiology, ESC) und der Europäischen Gesellschaft für Atherosklerose (European Atherosclerosis Society, EAS) eine intensive Senkung des LDL-Cholesterinspiegels in Abhängigkeit vom kardiovaskulären Risiko empfehlen, liegen viele Hochrisikopatientinnen und -patienten trotz verfügbarer lipidsenkender Therapien weiterhin über den empfohlenen LDL-Cholesterin-Zielwerten.3

Repatha wurde in der Europäischen Union ursprünglich 2015 für die Behandlung von Erwachsenen und Kindern mit primärer Hypercholesterinämie oder gemischter Dyslipidämie sowie zur Senkung des kardiovaskulären Risikos bei Erwachsenen mit nachgewiesener atherosklerotischer kardiovaskulärer Erkrankung (Atherosclerotic Cardiovascular Disease, ASCVD) zugelassen. Es wird erwartet, dass die Europäische Kommission in den kommenden Monaten eine endgültige Entscheidung über den Antrag trifft.

Informationen zur VESALIUS-CV-Studie
VESALIUS-CV ist eine globale klinische Phase-3-Studie, die doppelblind, randomisiert und placebokontrolliert durchgeführt wird und darauf abzielt, den Einfluss einer Senkung des LDL-C-Spiegels durch Evolocumab auf MACE bei Erwachsenen mit hohem kardiovaskulärem Risiko ohne vorangegangenen Herzinfarkt oder Schlaganfall zu untersuchen. Die Ergebnisse wurden im November 2025 im New England Journal of Medicine veröffentlicht. Repatha führte zu einer relativen Risikoreduktion um 25 % für den kombinierten Endpunkt aus Tod durch koronare Herzkrankheit (KHK), Herzinfarkt oder ischämischem Schlaganfall (3-P-MACE) sowie um 19 % für einen erweiterten kombinierten Endpunkt, der zusätzlich jegliche ischämiebedingte arterielle Revaskularisation umfasste (4-P-MACE). Evolocumab senkte zudem das Risiko eines Herzinfarkts um 36 %. Bei allen drei Endpunkten zeigte sich ein konsistenter Vorteil von Evolocumab gegenüber Placebo, einschließlich eines um 36 % verringerten Risikos für einen Herzinfarkt. In einer Lipid-Teilstudie führte die Zugabe von Evolocumab zu einer maximal verträglichen Dosis eines Statins und/oder Ezetimib bei den beobachteten Partientinnen und Patienten zu einer deutlichen Senkung der LDL-C-Werte, wobei der Medianwert bei 45 mg/dl lag, verglichen mit 109 mg/dl in der Placebo-Gruppe.

In die VESALIUS-CV-Studie wurden mehr als 12.000 Patientinnen und Patienten mit bekannter ASCVD oder Hochrisikodiabetes aufgenommen, die keine Herzinfarkte oder Schlaganfälle in der Anamnese aufwiesen, einen LDL-C-Wert von ≥ 90 mg/dl, oder ein Nicht-HDL-Cholesterin (Non-HDL-C) von ≥ 120 mg/dL oder ein Apolipoprotein B von ≥ 80 mg/dL aufwiesen und mit der höchstverträglichen Dosis eines Statins und/oder Ezetimib behandelt wurden. Der Medianwert des LDL-C-Ausgangswerts lag bei lokalen Laboruntersuchungen bei 122 mg/dl (IQR: 104–149 mg/dl). Die Teilnehmenden wurden randomisiert und erhielten zusätzlich zu einer optimierten lipidsenkenden Therapie entweder Evolocumab oder ein Placebo; sie wurden über einen Median von etwa 4,6 Jahren nachbeobachtet.

Amgens Engagement für Innovationen im Bereich Herz-Kreislauf-Erkrankungen
Amgen definiert die kardiometabolische Versorgung neu – mit modernster, auf der Humanbiologie basierender Forschung, die sich mit eng miteinander verbundenen Herz-Kreislauf- und Stoffwechselerkrankungen befasst, die zu schwerwiegenden Folgen oder zum Tod führen können.

Kardiometabolische Erkrankungen treten häufig gemeinsam auf und können zu schwerwiegenden Folgen oder zum Tod führen, obwohl sie behandelbar sind.4 Trotz Fortschritten bei lipidsenkenden und metabolischen Therapien bleibt ein erhebliches kardiovaskuläres Restrisiko bestehen, das durch einen anhaltend erhöhten LDL-C-Spiegel, genetisch bedingtes Lp(a) und eine durch Adipositas bedingte kardiometabolische Dysfunktion verursacht wird.5

Auf der Grundlage von mehr als 40 Jahren Spitzenforschung und Humangenetik definiert Amgen die kardiometabolische Versorgung und das Risikomanagement neu. Nach jahrelangen Erfolgen bei Herz-Kreislauf-Erkrankungen mit Repatha ist Amgen gut aufgestellt, um potenziell bahnbrechende Medikamente wie MariTide und Olpasiran auf den Markt zu bringen, die dazu beitragen, die Bedürfnisse der Patientinnen und Patienten in der kardiometabolischen Versorgung zu erfüllen und die vielfältigen, miteinander verknüpften Ursachen von Herz-Kreislauf- und Stoffwechselerkrankungen anzugehen.

Informationen zu Repatha
Repatha ist ein humaner monoklonaler Antikörper, der die Proprotein-Convertase Subtilisin/Kexin Typ 9 (PCSK9) hemmt. Repatha bindet an PCSK9 und verhindert, dass zirkulierendes PCSK9 an den Low-Density-Lipoprotein (LDL)-Rezeptor (LDLR) bindet. Dadurch wird der durch PCSK9 vermittelte Abbau des LDLR verhindert und ermöglicht, dass der LDLR wieder an die Oberfläche der Leberzellen zurückgeführt wird. Durch die Hemmung der Bindung von PCSK9 an den LDLR erhöht Repatha die Anzahl der verfügbaren LDLR, die LDL aus dem Blut entfernen können, und senkt dadurch den LDL-C-Spiegel.

Repatha ist einer der am umfassendsten untersuchten PCSK9-Hemmer, für den klinische und praxisbezogene Erkenntnisse aus verschiedenen Patientengruppen und mit unterschiedlichen kardiovaskulären Risikoprofilen vorliegen.6 Der klinische Nutzen und die Sicherheit von Repatha wurden über einen Zeitraum von 15 Jahren in 51 klinischen Studien mit über 57.000 Patientinnen und Patienten untersucht.7 Repatha ist der einzige PCSK9-Hemmer, der sowohl in der Hochrisiko-Primär- als auch in der Sekundärprävention eine signifikante Reduktion kardiovaskulärer Ereignisse nachweisen konnte, wobei die Patientinnen und Patienten mit nur einmal alle zwei Wochen verabreichtem Repatha eine drastische Senkung des LDL-C-Spiegels erreichten und aufrechterhalten konnten.8,9

Repatha wurde erstmals 2015 zugelassen und wurde seitdem weltweit bei mehr als 10 Millionen Patientinnen und Patienten angewendet.10  Im August 2025 erweiterte die US-amerikanische Arzneimittelbehörde (U.S. Food and Drug Administration, FDA) den zugelassenen Anwendungsbereich von Repatha auf Erwachsene mit erhöhtem Risiko für schwerwiegende unerwünschte kardiovaskuläre Ereignisse aufgrund eines unkontrollierten LDL-C-Spiegels. Repatha ist in 74 Ländern zugelassen, darunter in den USA, in Japan, in Kanada, in Australien sowie in allen 28 Mitgliedstaaten der Europäischen Union.11 In weiteren Ländern sind Zulassungsanträge anhängig.

Wichtige Produktinformationen für die EU

In Europa ist Repatha für folgende Anwendungsgebiete zugelassen:

Hypercholesterinämie und gemischte Dyslipidämie
Repatha ist bei Erwachsenen mit primärer Hypercholesterinämie (heterozygot, familiär und nicht familiär) oder gemischter Dyslipidämie als Ergänzung zu einer Diät indiziert:

in Kombination mit einem Statin oder einem Statin und anderen lipidsenkenden Therapien bei Patientinneb und Patienten, welche die LDL-C-Zielwerte mit der maximal verträglichen Dosis eines Statins nicht erreichen können, oder allein oder in Kombination mit anderen lipidsenkenden Therapien bei Patientinnen und Patienten, die Statine nicht vertragen oder bei denen die Einnahme eines Statins kontraindiziert ist. Homozygote familiäre Hypercholesterinämie
Repatha ist bei Erwachsenen und Jugendlichen ab zwölf Jahren mit homozygoter familiärer Hypercholesterinämie in Kombination mit anderen lipidsenkenden Therapien indiziert.

Atherosklerotische Herz-Kreislauf-ErkrankungenRepatha ist bei Erwachsenen mit nachgewiesener atherosklerotischer Herz-Kreislauf-Erkrankung oder mit hohem Risiko dafür indiziert, um das kardiovaskuläre Risiko durch Senkung der LDL-C-Werte zu verringern, und zwar als Ergänzung zur Korrektur anderer Risikofaktoren:

in Kombination mit der maximal verträglichen Dosis eines Statins, mit oder ohne weitere lipidsenkende Therapien, oder allein oder in Kombination mit anderen lipidsenkenden Therapien bei Patientinnen und Patienten, die Statine nicht vertragen oder bei denen die Einnahme eines Statins kontraindiziert ist. Dosierung
Primäre Hypercholesterinämie und gemischte Dyslipidämie bei Erwachsenen

Die empfohlene Dosis von Repatha beträgt entweder 140 mg alle zwei Wochen oder 420 mg einmal monatlich; beide Dosierungen sind klinisch gleichwertig.

Homozygote familiäre Hypercholesterinämie bei Erwachsenen und Jugendlichen ab zwölf Jahren

Die empfohlene Anfangsdosis beträgt 420 mg einmal monatlich. Nach zwölf Wochen Behandlung kann die Dosierungshäufigkeit auf 420 mg einmal alle zwei Wochen erhöht werden, falls kein klinisch relevantes Ansprechen erzielt wird. Patientinnen und Patienten, die sich einer Apherese unterziehen, können die Behandlung mit 420 mg alle zwei Wochen beginnen, um sie an ihren Apherese-Zeitplan anzupassen.

Wichtige Sicherheitshinweise
Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Auf diese Weise lassen sich schnell neue Sicherheitsinformationen ermitteln. Medizinisches Fachpersonal wird gebeten, alle vermuteten Nebenwirkungen zu melden.

Kontraindikationen: Überempfindlichkeit gegen den Wirkstoff oder einen der sonstigen Bestandteile.

Besondere Warnhinweise und Vorsichtsmaßnahmen: Nierenfunktionsstörung: Patientinnen und Patienten mit schwerer Nierenfunktionsstörung (definiert als eGFR < 30 ml/min/1,73 m2) wurden nicht untersucht. Repatha sollte bei Patientinnen und Patienten mit schwerer Nierenfunktionsstörung mit Vorsicht angewendet werden. Leberfunktionsstörung: Bei Patientinnen und Patienten mit mäßiger Leberfunktionsstörung wurde eine Verringerung der Gesamtexposition gegenüber Evolocumab beobachtet, was zu einer geringeren Wirkung im Hinblick auf die Senkung des LDL-C führen kann. Daher kann bei diesen Patientinnen und Patienten eine engmaschige Überwachung erforderlich sein. Patientinnen und Patienten mit schwerer Leberfunktionsstörung (Child-Pugh-Klasse C) wurden nicht untersucht. Repatha sollte bei Patientinnen und Patienten mit schwerer Leberfunktionsstörung mit Vorsicht angewendet werden. Trockener Naturkautschuk: Die Nadelabdeckung der vorgefüllten Glasspritze und des vorgefüllten Pens besteht aus trockenem Naturkautschuk (einem Latexderivat), der allergische Reaktionen hervorrufen kann. Natriumgehalt: Repatha enthält weniger als 1 mmol Natrium (23 mg) pro Dosis, d. h., es ist im Wesentlichen „natriumfrei".

Wechselwirkungen: Für Repatha wurden keine formellen Studien zu Wechselwirkungen mit anderen Arzneimitteln durchgeführt. Es wurden keine Studien zu pharmakokinetischen und pharmakodynamischen Wechselwirkungen zwischen Repatha und anderen lipidsenkenden Arzneimitteln als Statinen und Ezetimib durchgeführt.

Fruchtbarkeit, Schwangerschaft und Stillzeit: Es liegen keine oder nur begrenzte Daten zur Anwendung von Repatha bei Schwangeren vor. Repatha sollte während der Schwangerschaft nicht angewendet werden, es sei denn, der klinische Zustand der Frau erfordert eine Behandlung mit Evolocumab. Es ist nicht bekannt, ob Evolocumab in die Muttermilch übergeht. Ein Risiko für gestillte Neugeborene/Säuglinge kann nicht ausgeschlossen werden. Es liegen keine Daten zu den Auswirkungen von Evolocumab auf die Fruchtbarkeit beim Menschen vor.  

Nebenwirkungen: In zulassungsrelevanten, kontrollierten klinischen Studien wurden die folgenden häufigen (> 1/100 bis < 1/10) Nebenwirkungen berichtet: Grippe, Nasopharyngitis, Infektion der oberen Atemwege, Hautausschlag, Übelkeit, Rückenschmerzen, Gelenkschmerzen, Reaktionen an der Injektionsstelle. Eine vollständige Beschreibung der Nebenwirkungen finden Sie in der  Fachinformation .

Vorsichtsmaßnahmen bei der Einnahme von Arzneimitteln: Im Kühlschrank lagern (2 °C – 8 °C). Nicht einfrieren. Bewahren Sie die Fertigspritze oder den Fertigpen in der Originalverpackung auf, um sie vor Lichteinwirkung zu schützen. Nach Entnahme aus dem Kühlschrank kann Repatha bei Raumtemperatur (bis zu 25 °C) in der Originalverpackung aufbewahrt werden und muss innerhalb eines Monats aufgebraucht werden.

INDIKATIONEN IN DEN USA
Repatha® ist ein PCSK9-Hemmer (Proprotein-Convertase-Subtilisin/Kexin Typ 9), der für folgende Indikationen zugelassen ist:

Zur Senkung des Risikos schwerwiegender unerwünschter kardiovaskulärer Ereignisse (kardiovaskulärer Tod, Myokardinfarkt, Schlaganfall, instabile Angina pectoris, die einen Krankenhausaufenthalt erfordert, oder koronare Revaskularisation) bei Erwachsenen mit erhöhtem Risiko für diese Ereignisse. Als Ergänzung zu einer Diät und körperlicher Bewegung zur Senkung des LDL-Cholesterins (LDL-C) bei: Erwachsenen mit Hypercholesterinämie. Erwachsenen und pädiatrischen Patientinnen und Patienten ab zehn Jahren mit heterozygoter familiärer Hypercholesterinämie (HeFH). Erwachsenen und pädiatrischen Patientinnen und Patienten ab zehn Jahren mit homozygoter familiärer Hypercholesterinämie (HoFH). Die Sicherheit und Wirksamkeit von Repatha® bei Kindern mit HeFH oder HoFH unter zehn Jahren sowie bei Kindern mit anderen Formen der Hypercholesterinämie wurden nicht nachgewiesen. Die vollständigen Verschreibungsinformationen finden Sie auf www.Repatha.com.

 WICHTIGE SICHERHEITSINFORMATIONEN

Kontraindikation: Repatha® ist bei Patientinnen und Patienten kontraindiziert, bei denen in der Vergangenheit eine schwere Überempfindlichkeitsreaktion auf Evolocumab oder einen der Hilfsstoffe in Repatha® aufgetreten ist. Bei Patientinnen und Patienten, die mit Repatha® behandelt wurden, sind schwere Überempfindlichkeitsreaktionen einschließlich Angioödemen aufgetreten. Überempfindlichkeitsreaktionen: Bei Patientinnen und Patienten, die mit Repatha® behandelt wurden, wurden Überempfindlichkeitsreaktionen, einschließlich Angioödemen, berichtet. Sollten Anzeichen oder Symptome schwerwiegender Überempfindlichkeitsreaktionen auftreten, ist die Behandlung mit Repatha® abzubrechen, die Patientinnen und Patienten gemäß den geltenden Behandlungsstandards zu behandeln und sie so lange zu überwachen, bis die Anzeichen und Symptome abgeklungen sind. Nebenwirkungen bei Erwachsenen mit primärer Hypercholesterinämie: Die häufigsten Nebenwirkungen (> 5 % der mit Repatha® behandelten Patientinnen und Patienten und häufiger als unter Placebo) waren: Nasopharyngitis, Infektion der oberen Atemwege, Grippe, Rückenschmerzen und Reaktionen an der Injektionsstelle.Aus einer Zusammenfassung der 52-wöchigen Studie und sieben 12-wöchigen Studien: Lokale Reaktionen an der Injektionsstelle traten bei 3,2 % der mit Repatha® behandelten Patientinnen und Patienten und bei 3,0 % der mit Placebo behandelten Patientinnen und Patienten auf. Die häufigsten Reaktionen an der Injektionsstelle waren Hautrötungen, Schmerzen und Blutergüsse. Überempfindlichkeitsreaktionen traten bei 5,1 % der mit Repatha®behandelten Patientinnen und Patienten und bei 4,7 % der mit Placebo behandelten Patientinnen und Patienten auf. Die häufigsten Überempfindlichkeitsreaktionen waren Hautausschlag (1,0 % gegenüber 0,5 % bei Repatha® bzw. Placebo), Ekzem (0,4 % gegenüber 0,2 %), Erytheme (0,4 % gegenüber 0,2 %) sowie Urtikaria (0,4 % gegenüber 0,1 %).

Unerwünschte Wirkungen in der FOURIER-Studie zu kardiovaskulären Endpunkten: Die häufigsten Nebenwirkungen (> 5 % der mit Repatha® behandelten Patientinnen und Patienten und häufiger als unter Placebo) waren: Diabetes mellitus (8,8 % Repatha®, 8,2 % Placebo), Nasopharyngitis (7,8 % Repatha®, 7,4 % Placebo) sowie Infektionen der oberen Atemwege (5,1 % Repatha®, 4,8 % Placebo).Unter den 16.676 Patientinnen und Patienten, die zu Studienbeginn keinen Diabetes mellitus hatten, betrug die Inzidenz eines neu auftretenden Diabetes mellitus während der Studie bei den mit Repatha® behandelten Patientinnen und Patienten 8,1 %, verglichen mit 7,7 % bei den Patientinnen und Patienten, die ein Placebo erhielten.

Nebenwirkungen bei pädiatrischen Patientinnen und Patienten mit HeFH: Die häufigsten Nebenwirkungen (> 5 % der mit Repatha® behandelten Patientinnen und Patienten und häufiger als unter Placebo) waren: Nasopharyngitis, Kopfschmerzen, Schmerzen im Mund- und Rachenraum, Grippe und Infektion der oberen Atemwege. Nebenwirkungen bei Erwachsenen und Kindern mit HoFH: In einer 12-wöchigen Studie mit 49 Patientinnen und Patienten traten bei mindestens zwei mit Repatha® behandelten Patientinnen und Patienten folgende Nebenwirkungen auf, die häufiger auftraten als unter Placebo: Infektionen der oberen Atemwege, Grippe, Gastroenteritis und Nasopharyngitis. In einer offenen Verlängerungsstudie mit 106 Patientinnen und Patienten, darunter 14 Kinder, wurden keine neuen Nebenwirkungen beobachtet. Immunogenität: Repatha® ist ein humaner monoklonaler Antikörper. Wie bei allen therapeutischen Proteinen besteht auch bei Repatha® das Potenzial für Immunogenität. Die vollständigen Verschreibungsinformationen finden Sie hier.

Informationen zu Amgen
Amgen erforscht, entwickelt, produziert und liefert innovative Medikamente zur Bekämpfung einiger der schwersten Krankheiten der Welt. Amgen nutzt das Beste aus Biologie und Technologie und erreicht mit seinen Medikamenten Millionen von Patienten.

Vor mehr als 45 Jahren trug Amgen an seinem US-Hauptsitz in Thousand Oaks, Kalifornien, zur Gründung der Biotechnologiebranche bei und ist nach wie vor führend in der Innovation, indem es Technologien sowie humangenetische Daten nutzt, um über das heute Bekannte hinauszugehen. Amgen entwickelt eine breite und tiefe Pipeline und ein Portfolio von Medikamenten zur Behandlung von Krebs, Herzkrankheiten, Entzündungen, seltenen Krankheiten sowie Fettleibigkeit und mit Fettleibigkeit verbundenen Krankheiten.

Amgen wurde  wiederholt  für seine Innovationskraft und seine Unternehmenskultur ausgezeichnet, unter anderem von Fast Company und Forbes. Amgen gehört zu den 30 Unternehmen, die den Dow Jones Industrial Average® bilden, und ist auch Teil des Nasdaq-100-Index®, der die größten und innovativsten nicht-finanziellen Unternehmen umfasst, die an der Nasdaq-Börse nach Marktkapitalisierung notiert sind.

Für weitere Informationen besuchen Sie Amgen.com und folgen Sie Amgen auf X, LinkedIn, Instagram, YouTube, Facebook, TikTok und Threads.

Zukunftsgerichtete Aussagen
Diese Pressemitteilung enthält zukunftsgerichtete Aussagen, die auf den aktuellen Erwartungen und Einschätzungen von Amgen beruhen. Alle Aussagen, mit Ausnahme von Aussagen über historische Tatsachen, sind Aussagen, die als zukunftsgerichtete Aussagen angesehen werden könnten, einschließlich jeglicher Aussagen zu den Ergebnissen, Vorteilen und Synergien von Kooperationen oder potenziellen Kooperationen mit anderen Unternehmen (einschließlich BeOne Medicines Ltd. oder Kyowa Kirin Co., Ltd.), die Geschäftsentwicklung von Otezla® (Apremilast), unsere Übernahmen von ChemoCentryx, Inc., Dark Blue Therapeutics, Ltd. oder Horizon Therapeutics plc (einschließlich der voraussichtlichen Geschäftsentwicklung und des Ausblicks für das Geschäft von Horizon, der Geschäftsentwicklung und der Chancen sowie etwaiger potenzieller strategischer Vorteile, Synergien oder Chancen, die infolge einer solchen Übernahme erwartet werden) sowie Schätzungen zu Umsätzen, operativen Margen, Investitionsausgaben, Liquidität, anderer Finanzkennzahlen, erwarteter rechtlicher, schiedsgerichtlicher, politischer, regulatorischer oder klinischer Ergebnisse oder Praktiken, Verhaltensmuster oder Praktiken von Kunden und verschreibenden Ärzten, Erstattungsaktivitäten und -ergebnissen, Auswirkungen von Pandemien oder anderen weit verbreiteten Gesundheitsproblemen auf unser Geschäft, Ergebnisse, Fortschritte sowie anderer solcher Schätzungen und Ergebnisse. Zukunftsgerichtete Aussagen sind mit erheblichen Risiken und Unsicherheiten verbunden, einschließlich der nachstehend erläuterten Risiken und der Risiken, die ausführlicher in den von Amgen bei der Securities and Exchange Commission eingereichten Berichten beschrieben sind, darunter unser jüngster Jahresbericht auf Form 10-K sowie alle nachfolgenden regelmäßigen Berichte auf Form 10-Q und aktuellen Berichte auf Form 8-K. Sofern nicht anders angegeben, stellt Amgen diese Informationen zum Datum dieser Pressemitteilung zur Verfügung und übernimmt keine Verpflichtung, die in diesem Dokument enthaltenen zukunftsgerichteten Aussagen aufgrund neuer Informationen, zukünftiger Ereignisse oder aus anderen Gründen zu aktualisieren.

Keine zukunftsgerichtete Aussage kann garantiert werden, und die tatsächlichen Ergebnisse können erheblich von denen abweichen, die wir prognostizieren. Die Entdeckung oder Identifizierung neuer Produktkandidaten oder die Entwicklung neuer Indikationen für bestehende Produkte kann nicht garantiert werden und der Weg vom Konzept zum Produkt ist ungewiss. Folglich kann nicht garantiert werden, dass ein bestimmter Produktkandidat oder die Entwicklung einer neuen Indikation für ein bestehendes Produkt erfolgreich sein und zu einem kommerziellen Produkt werden wird. Außerdem sind die präklinischen Ergebnisse keine Garantie für die sichere und wirksame Leistung der Produktkandidaten beim Menschen. Die Komplexität des menschlichen Körpers kann durch Computer- oder Zellkultursysteme oder Tiermodelle nicht perfekt oder manchmal nicht einmal adäquat modelliert werden. Die Zeit, die wir benötigen, um klinische Studien abzuschließen und die behördliche Genehmigung für die Produktvermarktung zu erhalten, war in der Vergangenheit unterschiedlich lang, und wir erwarten ähnliche Schwankungen in der Zukunft. Selbst wenn die klinischen Studien erfolgreich verlaufen, können die Zulassungsbehörden die von uns gewählten Studienendpunkte als ausreichend für die Zulassung anzweifeln. Wir entwickeln Produktkandidaten sowohl intern als auch im Rahmen von Lizenzkooperationen, Partnerschaften und Joint Ventures. Produktkandidaten, die aus Beziehungen abgeleitet werden, können Gegenstand von Streitigkeiten zwischen den Parteien sein oder sich als weniger wirksam oder sicher erweisen, als wir zum Zeitpunkt des Eingehens einer solchen Beziehung angenommen haben. Außerdem könnten wir oder andere Sicherheits-, Nebenwirkungs- oder Herstellungsprobleme mit unseren Produkten, einschließlich unserer Geräte, feststellen, nachdem sie auf dem Markt sind.

Unsere Ergebnisse können von unserer Fähigkeit beeinflusst werden, neue und bestehende Produkte im In- und Ausland erfolgreich zu vermarkten, von klinischen und regulatorischen Entwicklungen bei aktuellen und zukünftigen Produkten, vom Umsatzwachstum kürzlich eingeführter Produkte, von der Konkurrenz durch andere Produkte, einschließlich Biosimilars, von Schwierigkeiten oder Verzögerungen bei der Herstellung unserer Produkte und von den globalen wirtschaftlichen Bedingungen, einschließlich derjenigen, die sich aus geopolitischen Beziehungen und Regierungsmaßnahmen ergeben. Darüber hinaus wird der Absatz unserer Produkte durch Preisdruck, politische und öffentliche Kontrolle sowie durch die Erstattungsrichtlinien von Drittanbietern, einschließlich Regierungen, privaten Versicherungsplänen und Managed-Care-Anbietern, beeinflusst. Er kann auch durch regulatorische, klinische und richtlinienbezogene Entwicklungen sowie durch nationale und internationale Trends in Richtung Managed Care und Kostendämpfung im Gesundheitswesen beeinflusst werden. Darüber hinaus unterliegen unsere Forschungs-, Test-, Preisgestaltungs-, Vermarktungs- sowie sonstigen Tätigkeiten einer umfassenden Regulierung durch in- und ausländische staatliche Aufsichtsbehörden. Unser Geschäft könnte durch staatliche Ermittlungen, Rechtsstreitigkeiten sowie Produkthaftungsansprüche beeinträchtigt werden. Zusätzlich könnte unser Geschäft durch die Einführung neuer Steuergesetze oder durch zusätzliche Steuerschulden beeinträchtigt werden. Weiterhin könnte der Schutz, den unsere Patente und Patentanmeldungen bieten, obwohl wir routinemäßig Patente für unsere Produkte und Technologien erhalten, von unseren Wettbewerbern angefochten, für ungültig erklärt oder umgangen werden, oder wir könnten in gegenwärtigen und künftigen Rechtsstreitigkeiten im Bereich geistiges Eigentum keinen Erfolg haben. Wir führen einen erheblichen Teil unserer kommerziellen Herstellungstätigkeiten in wenigen zentralen Einrichtungen durch, unter anderem in Puerto Rico, und sind zudem für einen Teil unserer Herstellungstätigkeiten auf Dritte angewiesen, und Lieferbeschränkungen könnten den Absatz bestimmter unserer derzeitigen Produkte sowie die Entwicklung bestimmter unserer Produktkandidaten einschränken. Der Ausbruch einer Krankheit oder eine ähnliche Bedrohung der öffentlichen Gesundheit sowie die öffentlichen und staatlichen Bemühungen, die Ausbreitung einer solchen Krankheit einzudämmen, könnten erhebliche nachteilige Auswirkungen auf die Versorgung mit Materialien für unsere Herstellungstätigkeiten, die Distribution unserer Produkte, die Vermarktung unserer Produktkandidaten sowie den Betrieb unserer klinischen Studien haben, und derartige Ereignisse könnten einen wesentlichen nachteiligen Einfluss auf unsere Produktentwicklung, unseren Produktabsatz, unser Geschäft sowie unsere Betriebsergebnisse haben. Wir sind bei der Entwicklung einiger unserer Produktkandidaten sowie bei der Vermarktung und dem Verkauf einiger unserer kommerziellen Produkte auf Kooperationen mit Dritten angewiesen. Zusätzlich stehen wir im Wettbewerb mit anderen Unternehmen, sowohl in Bezug auf viele unserer vermarkteten Produkte als auch bei der Entdeckung und Entwicklung neuer Produkte. Außerdem werden einige Rohstoffe, medizinische Geräte und Bauteile für unsere Produkte ausschließlich von Drittanbietern geliefert. Einige unserer Vertriebspartner, Kunden und Kostenträger haben in ihren Geschäftsbeziehungen mit uns eine erhebliche Kaufkraft. Die Entdeckung signifikanter Probleme mit einem Produkt, das einem unserer Produkte ähnlich ist und eine ganze Produktklasse betrifft, könnte erhebliche negative Auswirkungen auf den Absatz der betroffenen Produkte sowie auf unsere Geschäfts- und Betriebsergebnisse haben. Unsere Bemühungen, mit anderen Unternehmen, Produkten oder Technologien zusammenzuarbeiten oder diese zu erwerben, sowie die Geschäftsabläufe solcher Unternehmen zu integrieren oder die von uns erworbenen Produkte oder Technologien zu unterstützen, könnten nicht erfolgreich sein und könnten zu unerwarteten Kosten, Verzögerungen oder dazu führen, dass die Vorteile der Transaktionen nicht realisiert werden. Ein Ausfall, ein Cyberangriff oder eine Verletzung der Informationssicherheit unserer IT-Systeme könnte die Vertraulichkeit, Integrität und Verfügbarkeit unserer Systeme und Daten gefährden. Unser Aktienkurs ist volatil und kann durch eine Reihe von Ereignissen beeinflusst werden. Unser Geschäft und unsere Aktivitäten könnten durch das Scheitern oder das vermeintliche Scheitern bei der Erreichung unserer Nachhaltigkeitsziele negativ beeinflusst werden. Die Auswirkungen des globalen Klimawandels und der damit verbundenen Naturkatastrophen könnten sich negativ auf unser Geschäft und unseren Betrieb auswirken. Die globale Wirtschaftslage kann bestimmte Risiken, die unser Geschäft beeinträchtigen, verstärken. Unsere Geschäftsentwicklung könnte die Fähigkeit unseres Verwaltungsrats beeinträchtigen oder einschränken, eine Dividende zu beschließen, oder unsere Fähigkeit beeinträchtigen, eine Dividende zu zahlen oder unsere Stammaktien zurückzukaufen. Wir könnten nicht in der Lage sein, Zugang zu den Kapital- und Kreditmärkten zu für uns günstigen Bedingungen oder überhaupt zu erhalten.

KONTAKT: Amgen, Thousand Oaks
Madison Howard, 773-636-4910 (Medien)
Elissa Snook, 609-251-1407 (Medien)
Casey Capparelli, 805-447-1746 (Investoren)

LITERATURVERZEICHNIS

Martin, S. S., Aday, A. W., Allen, N. B., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Bansal, N., Beaton, A. Z., Commodore-Mensah, Y., Currie, M. E., Elkind, M. S. V., Fan, W., Generoso, G., Gibbs, B. B., Heard, D. G., Hiremath, S., Johansen, M. C., & Kazi, D. S. (2025). 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation, 151(8). https://doi.org/10.1161/cir.0000000000001303. MAC: REF-107092 Le, H. et al. (2025). Very High Prevalence of Nonoptimally Controlled Traditional Risk Factors at the Onset of Cardiovascular Disease. JACC, Volume 86 (Number 14) Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455. Eroglu T, Capone F, Schiattarella GG. The evolving landscape of cardiometabolic diseases. EBioMedicine. 2024 Nov;109:105447. doi: 10.1016/j.ebiom.2024.105447. Online veröffentlicht am 4. November 2024. PMID: 39500010; PMCID: PMC11570325.  Tan SH, Wu JL, Zhuo SX, Zhang Y, Wang M. Residual risk in atherosclerotic cardiovascular disease after statin therapy: Clinical mechanisms and management strategies. World J Cardiol. 26. Februar 2026; 18(2):114960. doi: 10.4330/wjc.v18.i2.114960. PMID: 41694036; PMCID: PMC12897005. Data on File. Amgen, 2025. Data on File. Amgen, 2025. Ndumele, C. E., & Blumenthal, R. S. (2025). VESALIUS and the Anatomy of High-Risk Prevention. New England Journal of Medicine. https://doi.org/10.1056/nejme2515447 Marston, N. A., Bohula, E. A., Bhatia, A. K., et al. (2026). Evolocumab to reduce first major cardiovascular events in patients without known significant atherosclerosis and with diabetes: Results from the VESALIUS‑CV trial. JAMA. https://doi.org/10.1001/jama.2026.3277 Data on File. Amgen, 2026. Data on File. Amgen, 2025.

Regeneron Pharmaceuticals, Inc. (REGN) Q2 2026 Earnings Call July 30, 2026 8:30 AM EDT

Company Participants

Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis
Leonard Schleifer - Co-Founder, President, CEO & Co-Chairman
George Yancopoulos - Co-Founder, President, Chief Scientific Officer & Co-Chairman
Marion McCourt - Executive Vice President of Commercial
Christopher Fenimore - Executive VP of Finance & CFO

Conference Call Participants

Christopher Raymond - Raymond James & Associates, Inc., Research Division
Taylor Hanley - JPMorgan Chase & Co, Research Division
Tyler Van Buren - TD Cowen, Research Division
Mario Joshua Chazaro Cortes - Evercore ISI Institutional Equities, Research Division
Salveen Richter - Goldman Sachs Group, Inc., Research Division
Alexandria Hammond - Wolfe Research, LLC
Tazeen Ahmad - BofA Securities, Research Division
Evan Seigerman - BMO Capital Markets Equity Research
Gregory Renza - Truist Securities, Inc., Research Division
Carter Gould - Cantor Fitzgerald & Co., Research Division
Geoffrey Meacham - Citigroup Inc., Research Division

Presentation

Operator

Welcome to the Regeneron Pharmaceuticals Second Quarter 2026 Earnings Conference Call. My name is Michelle, and I'll be your operator for today's call. [Operator Instructions] Please note that this conference call is being recorded.

I will now turn the call over to Ryan Crowe, Senior Vice President, Investor Relations. You may begin.

Ryan Crowe
Senior Vice President of Investor Relations & Strategic Analysis

Thank you, Michelle. Good morning, good afternoon, and good evening to everyone listening around the world. Thank you for your interest in Regeneron, and welcome to our second quarter 2026 earnings conference call. An archive and transcript of this call will be available on the Regeneron Investor Relations website shortly after our call concludes.

Joining me on today's call are Dr. Leonard Schleifer, Co-Founder, Board, Co-Chair, President and Chief Executive Officer; Dr. George Yancopoulos, Co-Founder, Board, Co-Chair, President and Chief Scientific Officer; Marion McCourt, Executive Vice President, Commercial; and Chris Fenimore, Executive Vice President, Finance and Chief Financial Officer.

The Coinbase logo is seen in this illustration created on November 3, 2025. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab

CompaniesNEW YORK, July 30 (Reuters) - Coinbase (COIN.O), opens new tab won the dismissal on Thursday of much of a lawsuit in which customers accused the largest U.S. cryptocurrency exchange of ​illegally selling securities without registering as an exchange or broker-dealer.

Customers sued ‌over 60 tokens, including XRP and dogecoin, that they claimed were unregistered securities, seeking unspecified damages in the proposed class action.

The Reuters Daily Briefing newsletter provides all the news you need to start your day. Sign up here.

U.S. District Judge Paul Engelmayer in Manhattan dismissed all claims based ​on "matched" transactions where Coinbase paired customers' buy and sell orders. These accounted ​for an estimated 99.97% of trading volume, equal to hundreds of ⁠billions of dollars.

The judge also said customers may pursue claims over "inventory" transactions, where ​Coinbase fills orders from tokens it owns. These accounted for the remaining trading volume, ​comprising at least $178 million in sales.

Lawyers for the customers did not immediately respond to requests for comment. Coinbase and its lawyers did not immediately respond to similar requests.

Like other cryptocurrency industry ​participants, Coinbase has seen a rollback of regulatory oversight under the second Trump ​administration.

The lawsuit's outcome turned on whether Coinbase qualified as a statutory seller under the federal Securities ‌Act ⁠of 1933 and state "blue sky" laws designed to prevent fraudulent securities sales.

Engelmayer said Coinbase was not a statutory seller for matched transactions because it did not pass ownership of tokens to buyers, and did not induce, or "solicit," the transactions merely by ​providing basic overviews of ​tokens and their ⁠price histories.

Coinbase was a statutory seller for inventory transactions, however, because it passed title of tokens to buyers, and acted ​as a dealer and underwriter, Engelmayer said.

The lawsuit began in ​2021. Engelmayer dismissed ⁠other federal securities law claims in 2023.

Digital Chamber, a cryptocurrency trade group, supported Coinbase, saying an expansive definition of statutory seller could stifle innovation and drive trading volume ⁠to non-U.S. ​exchanges.

Last year, the U.S. Securities and Exchange Commission ended ​a lawsuit it brought in 2023 that accused Coinbase of allowing trading in tokens that should have ​been registered as securities.

Reporting by Jonathan Stempel in New York; Editing by Joe Bavier

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Crocs, Inc. (NASDAQ:CROX) shares fell almost 10% on Thursday after the footwear company issued a weaker-than-expected third quarter outlook, as tariff pressures and continued weakness at its HEYDUDE brand weighed on sentiment, despite a second-quarter earnings and revenue beat.

The company forecast Q3 adjusted earnings per share of $3.20 to $3.30 on roughly flat revenue, below Wall Street expectations for adjusted EPS of around $3.53 to $3.55 and revenue of about $1 billion. Crocs attributed the outlook to ongoing tariff impacts and product mix pressures.

For the second quarter of 2026, Crocs reported adjusted earnings per share of $4.55, above analyst estimates of $4.32 to $4.35.

Revenue came in at $1.18 billion, topping expectations of $1.15 billion and rising 2.6% from the prior year.

The company’s core Crocs brand surpassed $1 billion in quarterly revenue for the first time, with sales increasing 4.3% year over year to $1 billion. Direct-to-consumer revenue for the brand rose 12.9%, while wholesale revenue declined 5%.

HEYDUDE continued to face challenges, with quarterly revenue falling 5.7% to $179 million. Direct-to-consumer sales increased 7.2%, but wholesale revenue declined 17.2%.

Overall gross margin declined to 59.4% from 61.7% a year earlier, while adjusted gross margin fell 170 basis points to 60% as tariff-related costs affected profitability. Adjusted operating income declined 4.5% to $296 million, with adjusted operating margin narrowing to 25.1% from 26.9%.

Crocs raised its full-year 2026 outlook, now expecting revenue growth of approximately 1% to 2%, compared with its previous forecast of down 1% to up 1%. Adjusted diluted earnings per share guidance was increased to a range of $13.70 to $14, up from the prior range of $13.20 to $13.75.

“Our results reflect broad consumer demand across both brands, healthy direct-to-consumer growth, and strong consumer response to new product innovation,” Crocs CEO Andrew Rees said in a statement.  

The company also announced that its board increased its share repurchase authorization by $1.5 billion, leaving approximately $2 billion available for future buybacks. During the quarter, Crocs repurchased about 2.3 million shares for $251 million.

Yum China Holdings, Inc. (YUMC) Q2 2026 Earnings Call July 30, 2026 7:00 AM EDT

Company Participants

Florence Lip - Senior Director of Investor Relations
Joey Wat - CEO & Executive Director
Adrian Ding - Chief Financial Officer

Conference Call Participants

Michelle Cheng - Goldman Sachs Group, Inc., Research Division
Chen Luo - BofA Securities, Research Division
Lillian Lou - Morgan Stanley, Research Division
Kin Shun Ling - Jefferies LLC, Research Division
Xiaopo Wei - Citigroup Inc. Exchange Research
Christine Peng - UBS Investment Bank, Research Division
Yushen Wang - CLSA Limited, Research Division

Presentation

Operator

Good day, everyone, and thank you for standing by. Welcome to Yum China's Second Quarter 2026 Earnings Conference Call.

[Operator Instructions]

Please be advised that today's conference is being recorded. Now it's my pleasure to hand the conference to Florence Lip, Senior Director of Investor Relations. Please proceed.

Florence Lip
Senior Director of Investor Relations

Thank you, operator. Hello, everyone, and welcome to Yum China's Second Quarter 2026 Earnings Conference Call. With me on the call are our CEO, Ms. Joey Wat; and our CFO, Mr. Adrian Ding. Before we begin, I will remind everyone that our remarks and investor materials contain forward-looking statements. These are subject to future events and uncertainties, and actual results may differ materially.

Please refer to these forward-looking statements together with the cautionary statement in our earnings release and the risk factors included in our SEC filings. We'll also be talking about non-GAAP financial measures. We encourage you to review the comparable GAAP measures, along with the reconciliation of non-GAAP and GAAP measures provided in our earnings release, which is available on our Investor Relations website at ir.yumchina.com.

You can also find both the webcast replay and a PowerPoint presentation on our IR website. Please note that all year-over-year growth rates discussed today exclude the impact

Flowserve Corporation (FLS) Q2 2026 Earnings Call July 30, 2026 8:30 AM EDT

Company Participants

Brian Ezzell - Treasurer and VP of Investor Relations & Corporate Finance
Robert Rowe - President, CEO & Director
Amy Schwetz - Senior VP, CFO & Interim Principal Accounting Officer

Conference Call Participants

Andrew Kaplowitz - Citigroup Inc., Research Division
Deane Dray - RBC Capital Markets, Research Division
Michael Halloran - Robert W. Baird & Co. Incorporated, Research Division
Adam Farley - Stifel, Nicolaus & Company, Incorporated, Research Division
Amit Mehrotra - UBS Investment Bank, Research Division
Christopher Grenga - TD Cowen, Research Division
Andrew Obin - BofA Securities, Research Division

Presentation

Operator

Good day, everyone, and welcome to the Flowserve Second Quarter 2026 Earnings Call. Today's conference is being recorded.

At this time, I would like to turn the conference over to Mr. Brian Ezzell, Vice President of Investor Relations. Please go ahead, sir.

Brian Ezzell
Treasurer and VP of Investor Relations & Corporate Finance

Thank you, and good morning, everyone. Welcome to Flowserve's Second Quarter 2026 Business Update. I'm joined by Scott Rowe, Flowserve's President and Chief Executive Officer; and Flowserve Chief Financial Officer, Amy Schwetz. Following Scott, and Amy's prepared remarks, we'll open the call for questions.

Turning to Slide 2. Our discussion will contain forward-looking statements that are based upon information available as of today. Actual results may differ due to risks and uncertainties. Refer to additional information, including our note on non-GAAP measures in our press release, earnings presentation and SEC filings, which are available on our website.

With that, I will turn it over to Scott.

Robert Rowe
President, CEO & Director

Thank you, Brian, and good morning, everyone. Turning to Slide 3. I'd like to begin by thanking our associates around the world for their hard work, disciplined execution and resilience in what remains a dynamic environment. The second quarter was

SummaryCompaniesAmeren projects winter 2032 capacity shortfall of about 1,500 MW after plant startupShortfall grows to about 2,300 MW in 2033, Ameren estimatesRegulatory process starts with August 20 prehearing conference before Missouri Public Service CommissionJuly 30 (Reuters) - Ameren's planned mega gas plant for the Midwest will still leave the utility ‌short of the power and reserves needed to meet surging data center demand, the company's own analysis showed ahead of a key approval process next month.

The projected shortfall highlights mounting strain on U.S. power grids as data center demand grows faster ​than the generation and transmission capacity needed to support it.

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

St. Louis-based Ameren's urgency for the project ​is acute after signing contracts this year to provide electricity to data centers in ⁠development by Amazon (AMZN.O), opens new tab and Alphabet's Google (GOOGL.O), opens new tab in rural Missouri.

Ameren (AEE.N), opens new tab says the 2,100-megawatt West Alton Energy Center is ​necessary, but would not fully restore the reserve cushion needed to meet projected demand. The project is planned for ​a site next to a coal plant on the banks of the Mississippi River about 28 miles (45 km) northwest of St. Louis.

"The company's resource capacity still falls well short of the total demand" and planned reserve margin, Ameren Director of Corporate ​Analysis Matt Michels said in July 24 testimony filed with the Missouri Public Service Commission.

An August 20 ​prehearing conference will kick off the regulatory process for Ameren to obtain approval to construct the power plant.

Ameren estimates the ‌plant would ⁠come online in late 2031. But Ameren's capacity shortfall in the winter of 2032, for example, would equal about 1,500 MW and grow to about 2,300 MW the following year, Michels said in his testimony.

Ameren executives say the utility also will build capacity by enhancing existing power sources, developing solar and battery energy storage ​sites and purchasing power from ​the regional grid.

Ameren's service ⁠area falls within the Midcontinent ISO, which manages the flow of electricity for a territory that includes all or part of 15 U.S. states in the Midwest ​and South.

The total return on Ameren's stock over the past 12 months is ​12.7%, outpacing ⁠the 8.4% for the S&P 500 Utilities Sector (.SPLRCU), opens new tab, as investors anticipate strong earnings growth over the next decade.

"Ameren anticipates more than $70 billion of additional investment opportunities over the next 10 years, providing a long runway of growth," Morningstar ⁠analyst Andrew ​Bischof wrote this week in a research note.

"The most attractive ​opportunities are supporting data center development in Illinois and Missouri, new generation in Missouri, modernizing the grid in Illinois and Missouri, and transmission ​expansion across the Midcontinent electric grid," Bischof said.

Reporting By Tim McLaughlin; editing by Timothy Gardner and Bill Berkrot

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Key Takeaways TransUnion topped Q2 estimates, with adjusted EPS up 13.9% and revenues rose 14.9% year over year.U.S. Markets grew 11% as Financial Services surged 18%, while International revenues climbed 27% y/y.TRU raised 2026 guidance on strong first-half execution and improved contributions from Mexico. TransUnion (TRU - Free Report) reported impressive second-quarter 2026 results, with both earnings and revenues beating the Zacks Consensus Estimate.

TRU’s adjusted earnings of $1.23 per share topped the Zacks Consensus Estimate by 7.9% and increased 13.9% from the year-ago quarter’s level. The performance extended the company’s strong start to 2026.

Revenues of $1.31 billion surpassed the consensus estimate by 1.7% and rose 14.9% year over year. Organic constant-currency revenues grew 10% from the year-ago quarter, led by U.S. Financial Services and Emerging Verticals.

The better-than-expected results impressed investors, as the stock has gained 8.4% since the company released results on July 28.

TRU’s shares have plunged 12% over the past year compared with the industry’s 11.4% decrease. The Zacks S&P 500 Composite has risen 19.6% over the same time frame.

TRU's U.S. Markets Growth BroadensU.S. Markets revenues increased 11% to $992.7 million. Financial Services revenues climbed 18% to $496.3 million, reflecting strength across credit and non-credit offerings, pricing actions and new client wins.

Excluding FICO mortgage royalties, Financial Services growth was 10%. Credit Card and Banking revenues increased 6%, while Consumer Lending and Auto each grew 8%. Mortgage revenues advanced 37%, or 15% excluding the royalty benefit, despite a 7% decline in inquiries.

Emerging Verticals revenues rose 9% to $353.9 million. Insurance delivered its eighth consecutive quarter of double-digit growth, while technology, retail and e-commerce produced high-single-digit growth.

Consumer Interactive revenues declined 3% to $142.5 million. Growth through indirect channels was offset by continued weakness in the direct-to-consumer business.

TransUnion's International Growth AcceleratesInternational revenues increased 27% to $320.8 million, including the contribution from Trans Union de Mexico. On an organic constant-currency basis, growth accelerated to 6% from flat performance in the first quarter.

Canada revenues rose 10% to $46.4 million, supported by financial services, fintech and insurance demand. The United Kingdom revenues increased 9% to $73.5 million, benefiting from market-share gains and new business across banking and fintech.

India revenues returned to growth, rising 8% on a constant-currency basis, as credit volumes improved and new client wins strengthened. Latin America grew 5% organically, while Africa advanced 5%. Asia Pacific declined 7%, although management expects the region to return to growth in the second half.

Trans Union de Mexico continued to perform ahead of the company’s acquisition assumptions. Management plans to expand its data coverage, introduce TruIQ analytics and eventually migrate the business to the OneTru platform.

TRU's Margin Picture Reflects Royalty DragAdjusted EBITDA increased 12% to $456.1 million. The adjusted EBITDA margin contracted 90 basis points to 34.8%, with management attributing the decline entirely to FICO mortgage royalties.

U.S. Markets adjusted EBITDA rose 7% to $361 million, while its margin declined to 36.4% from 37.9%. International adjusted EBITDA increased 27% to $136.8 million, while its margin held steady at 42.7%.

GAAP net income attributable to TransUnion increased to $143.4 million from $109.6 million. Diluted GAAP earnings were 74 cents per share, up from 56 cents in the prior-year quarter.

TransUnion's Cash Flow Supports BuybacksTransUnion ended June with $839.1 million in cash and cash equivalents and $5.59 billion in total debt. Its leverage ratio declined to 2.6X, supported by adjusted EBITDA growth.

Cash provided by operating activities totaled $459.1 million in the first six months of 2026, up from $343.8 million a year earlier. Capital expenditures decreased to $134.4 million from $145.4 million.

The company repurchased roughly $150 million of shares through July, including 2.1 million shares at an average price of about $71. Management expects second-half repurchases to be at least comparable to the first-half pace while continuing to target leverage below 2.5X.

TRU’s Q3 & 2026 OutlookFor the third quarter, TransUnion expects revenues to be between $1.292 billion and $1.310 billion, representing reported growth of 11-12%. The Zacks Consensus Estimate for the same is pegged at $1.31 billion. Organic constant-currency growth is projected at 6-8%.

TRU guided its third-quarter 2026 adjusted earnings to be between $1.18 and $1.21 per share, with the midpoint of $1.195 per share being lower than the Zacks Consensus Estimate of $1.23 per share. Adjusted EBITDA is anticipated to be between $455 million and $463 million, with a margin of 35.2-35.4%.

For 2026, the company raised its revenue outlook to $5.127-$5.162 billion, implying growth of 12-13%. The midpoint of the guided range ($5.145 billion) is marginally higher than the Zacks Consensus Estimate of $5.14 billion. Organic constant-currency growth remains projected at 8-9%.

Adjusted EBITDA is expected between $1.807 billion and $1.827 billion. Adjusted earnings guidance increased to $4.75-$4.83 per share from the earlier range of $4.68-$4.75, reflecting stronger first-half execution and improved contributions from Mexico. The Zacks Consensus Estimate for the same is pegged at $4.75 per share.

TransUnion currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Recent Earnings SnapshotsWEX Inc. (WEX - Free Report) reported better-than-expected second-quarter 2026 results. WEX’s adjusted earnings of $5.35 per share outpaced the Zacks Consensus Estimate by 5.3% and increased 35.4% from the year-ago quarter. WEX’s revenues of $753.5 million topped the consensus estimate by 1.8% and improved 14.2% year over year.

Waste Connections, Inc. (WCN - Free Report) posted impressive second-quarter 2026 results. WCN’s adjusted earnings of $1.50 per share outpaced the consensus mark by 11.1% and rose 16.3% from the year-ago quarter. WCN’s total revenues of $2.56 billion surpassed the consensus mark by 1.1% and increased 6.4% year over year.

Key Takeaways Alaska Air now serves 140 destinations after combining operations under one FAA certificate. Atmos Rewards lifted loyalty revenue 23% to $258 million in the second quarter of 2026. Revenue rose 9.7% to $4.07 billion, while operating expenses surged 24% amid fuel and weather pressure. Alaska Air Group (ALK - Free Report) is using its Hawaiian Airlines combination to move beyond a mostly regional identity. The company now serves more than 140 destinations across North America, Latin America, Asia, the Pacific and Europe.

The expanded platform gives ALK a larger growth runway, but the payoff is not automatic. Integration execution, cost discipline and operational reliability will decide whether the broader network becomes durable investor value.

Alaska Air Builds a Broader NetworkAlaska and Hawaiian combined operations under a single FAA operating certificate in October 2025, while keeping Alaska Airlines and Hawaiian Airlines as separate guest-facing brands. That structure lets ALK pursue operating integration without giving up brand equity in core markets.

The strategic value sits in the combined inventory, reservation capability and geographic fit. Hawaiian adds Pacific depth and long-haul relevance, while Alaska contributes an established West Coast network. Delta Air Lines (DAL - Free Report) and United Airlines Holdings (UAL - Free Report) remain larger global network competitors, making Alaska’s expanded Seattle, Hawaii and Pacific platform important to its relevance.

ALK Expands Loyalty Through Atmos RewardsAtmos Rewards, launched in August 2025, combines Mileage Plan and HawaiianMiles into one loyalty program. A single platform can make points more useful across a larger route map, which may lift engagement as members see more earning and redemption options.

Loyalty also matters financially. In 2025, loyalty program other revenue contributed 6% of Alaska Air’s $14.24 billion in total operating revenue. In the second quarter of 2026, loyalty program other revenue rose 23% year over year to $258 million, while loyalty cash remuneration increased 19%.

Management cited strong adoption of Atmos Rewards and higher account activity, including Hawaiian-related growth, as integration friction eased after the single passenger service system transition.

Alaska Air Modernizes Its Fleet and ProductFleet renewal is another pillar of the long-term plan. Alaska has extended its Boeing delivery stream through 2035, giving it a path to replace older aircraft and support measured growth over time.

Newer aircraft can improve per-seat fuel efficiency, a meaningful lever for an airline facing volatile fuel prices. ALK also plans fleetwide Starlink Wi-Fi installation by the end of 2027, with one-third of the fleet already equipped as of the second-quarter call.

Product upgrades are moving in the same direction. Alaska completed 737 cabin retrofits, adding 1.3 million incremental first and premium class seats, and the Hawaiian combination expands premium long-haul offerings, including lie-flat seating on select routes.

ALK Balances Demand Strength With Cost PressureDemand has held up despite disruptions. Second-quarter 2026 revenues increased 9.7% year over year to $4.07 billion, premium revenues grew 15%, managed corporate revenues rose 30% and unit revenues improved 8.6%.

Driven by the positive revenue outlook, the Zacks Consensus Estimate for revenues for third quarter 2026, fourth quarter 2026 and full-year 2026 and 2027 reflect year-over-year growth.

Image Source: Zacks Investment Research

The counterweight is cost pressure. Historic rainstorms in Hawaii reduced system unit revenue by roughly 3 percentage points in the quarter. Total operating expenses surged 24%, fuel expense rose 86%, wages and benefits increased 6%, and landing fees and other rentals climbed 10%.

A broader network can support revenue growth, especially in premium, loyalty, cargo and international flying. It also raises operating complexity during integration, when weather, technology cutovers, airport costs, labor inflation and fuel swings can offset revenue progress.

Alaska Air’s Mixed Signals Shape the OutlookThe bottom line is that Alaska Air’s transformation has strategic logic, but investors still need evidence that scale can translate into stronger earnings. The Hawaiian integration gives ALK more routes, more loyalty utility and a broader premium product set, but airline execution risk remains high.

The stock currently carries a Zacks Rank #3 (Hold). That ranking points to a neutral near-term setup rather than a clear buy signal, consistent with the mix of supportive demand and meaningful cost headwinds. You can see the complete list of today’s Zacks #1 Rank stocks (Strong Buy) here.

ALK’s Value Score of B reflects a comparatively attractive valuation profile, including a price-to-sales ratio of 0.4. The Growth Score of F and Momentum Score of F are less favorable, signaling that earnings growth characteristics and share-price trends remain weak.

The VGM Score of D brings those style factors together. For now, the integration opportunity has not yet translated into a broad-based style-score profile, keeping the investment case balanced rather than decisively positive.

Key Takeaways GFS is expected to post higher Q2 revenues, supported by AI networking, communications and data centers.GlobalFoundries expanded AI and quantum offerings through new launches and an acquisition during the quarter.GFS faces weak smartphone demand, macro uncertainty and geopolitical risks ahead of Q2 earnings. GlobalFoundries Inc. (GFS - Free Report) is set to report second-quarter 2026 results on Aug. 5, before the opening bell. In the trailing four quarters, the company delivered an earnings surprise of 13.97%, beating estimates on all occasions.

The leading semiconductor manufacturer is expected to witness top-line growth year over year, backed by healthy demand in AI networking, communications infrastructure and data center space. Strength in automotive and recovery in industrial IoT are positive factors. However, weak smartphone market, macro headwinds, geopolitical uncertainty and customer concentration are concerning.

Factors at PlayDuring the quarter, GlobalFoundries strengthened its position in AI infrastructure by introducing the SCALE (Silicon Photonics Co-packaged Advanced Light Engine) optical module solution for co-packaged optics. The solution is expected to have boosted the company's silicon photonics portfolio and drive customer engagement in the AI networking domain.

GlobalFoundries also expanded its presence in Physical AI through the completion of the acquisition of Synopsys' Processor IP Solutions business. The buyout is likely to have strengthened prospects across automotive, industrial robotics and edge AI applications.

During the quarter, GlobalFoundries launched Quantum Technology Solutions, a dedicated business focused on manufacturing quantum hardware. The initiative is backed by customer engagements, government support and partnerships with leading quantum computing companies. It is expected to have enhanced the company's exposure to high-performance computing markets.

Innovative product launches and solid demand in AI infrastructure, communications and data center domains are expected to have a positive impact in the second quarter. However, weakness in the smartphone vertical and ongoing macro uncertainty remain concerns. The company faces competition from other major players in the industry such as TSMC, Tower Semiconductor and others.

Overall ExpectationsFor the June quarter, the Zacks Consensus Estimate for total revenues is pegged at $1.76 billion, indicating an improvement from the year-ago quarter’s reported figure of $1.69 billion. The consensus estimate for adjusted earnings per share is pegged at 44 cents, indicating growth from 42 cents reported a year ago.

Earnings WhispersOur proven model does conclusively predict a likely earnings beat for GFS for the second quarter. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. That is exactly the case here.

Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is +0.33%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: GFS carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.

Other Stocks to ConsiderHere are some other stocks you may want to consider, as our model shows that these, too, have the right combination of elements to post an earnings beat this season:

Sandisk Corporation (SNDK - Free Report) is set to release quarterly numbers on Aug. 5. It has an Earnings ESP of +4.13% and sports a Zacks Rank #1.

The Earnings ESP for Arista Networks, Inc. (ANET - Free Report) is +3.08%, and it carries a Zacks Rank of 2. The company is scheduled to report quarterly numbers on Aug. 4.

The Earnings ESP for Advanced Micro Devices, Inc. (AMD - Free Report) is +1.56%, and it carries a Zacks Rank of 2. The company is scheduled to report quarterly numbers on Aug. 4.

Key Takeaways Gartner's Q2 revenues are expected to fall 2.4% y/y to $1.7 billion as Insights and Consulting weaken.Insights revenues may decline 2.5% as contract value drops 10.7% amid weaker engagement and retention.EPS is projected to rise 6.8% to $3.77, supported by expense management and share repurchases. Gartner Inc. (IT - Free Report) will release second-quarter 2026 results on Aug. 4, before market open.

IT has an impressive earnings surprise history. In the four trailing quarters, it surpassed the Zacks Consensus Estimate, with an average surprise of 10.6%.

Gartner’s Q2 ExpectationsThe Zacks Consensus Estimate for the top line is pinned at $1.7 billion. It is expected to recede 2.4% from the year-ago quarter’s actual. Revenues are expected to have sunk primarily due to a weaker performance in Insights, which contributes the majority of the top line. A slowdown in Consulting revenues is predicted to have affected the top line.

The consensus mark for Insights revenues is $1.3 billion, implying a 2.5% year-over-year decline. We expect the segment to have sustained a blow due to shrinking contract value, as evidenced by a Zacks Consensus Estimate of $4.2 billion, suggesting a 10.7% year-over-year drop. This anticipated cut down in contract value is likely to have stemmed from a slump in client engagement and retention.

For Conferences, the Zacks Consensus Estimate is pinned at $218.9 million. The figure is expected to move up 3.5% from the year-ago quarter’s actual. As mentioned by Craig Safian, the CFO, during first-quarter 2026 earnings, Gartner plans to hold 56 in-person destination conferences in 2026. The trajectory to complete these conferences is anticipated to have supported growth.

The consensus estimate for Consulting revenues is anticipated to plunge 13.5% year over year. This segment’s revenues are tracking at $134.5 million. Contract optimization is highly variable, which is anticipated to have potentially shifted revenue realization during the second quarter of 2026, affecting this segment.

The consensus estimate for earnings per share is $3.77, implying a 6.8% year-over-year escalation. The factors, including agile expense management, leading to margin expansion and continued share repurchases lowering share count, are expected to have supported this upsurge in the bottom line.

What Our Model Says About ITOur proven model does not conclusively predict an earnings beat for Gartner this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.

IT has an Earnings ESP of -1.48% and a Zacks Rank of 4 (Sell) at present.

Stocks to ConsiderHere are a few stocks, according to our model, which have the right combination of elements to beat on earnings this season.

Duolingo, Inc. (DUOL - Free Report) : The Zacks Consensus Estimate for second-quarter 2026 revenues is pegged at $297.4 billion, suggesting a 17.9% jump from the year-ago quarter’s actual. For earnings, the consensus mark is set at 61 cents per share, a 33% plunge from the year-ago quarter. DUOL beat the consensus estimate in the trailing four quarters, with an average surprise of 32.3%.

DUOL has an Earnings ESP of +9.02% and a Zacks Rank of 2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

It is scheduled to declare second-quarter 2026 results on Aug. 5.

Dave Inc. (DAVE - Free Report) : The Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is $169.8 million, suggesting a 28.9% jump from the year-ago quarter’s actual. For earnings, the consensus mark is $3.69 per share, indicating 17.5% growth. DAVE beat the consensus estimate for earnings in the trailing four quarters, with an average surprise of 45.8%.

DAVE has an Earnings ESP of +1.42% and a Zacks Rank of 2 at present. The company is scheduled to declare second-quarter 2026 results on Aug. 5.

Key Takeaways RVTY to report Q2 2026 results on Aug. 4, with revenues seen down 2.2% and EPS up 4.2% year over year.Revvity saw improving demand in pharma, biotech and academia, while Diagnostics remained the key driver.RVTY expects cost cuts, productivity and operating leverage to support margins despite tariff and FX headwinds Revvity, Inc. (RVTY - Free Report) is slated to report second-quarter 2026 results on Aug. 4, before market open.

In the last reported quarter, the company delivered an earnings surprise of 3.92%. RVTY’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 3.81%.

Revvity’s first-quarter performance reflected improving momentum, supported by resilient Diagnostics performance and early signs of stabilization in Life Sciences. Life Sciences demand likely started recovering during the second quarter amid improving academic and government spending and a gradual recovery in pharma and biotech activity. Diagnostics, however, is expected to have remained the primary growth driver, aided by strength in reproductive health and immunodiagnostics, partially offset by persistent China-related headwinds, positioning the company for a cautiously improving near-term outlook.

So far this year, RVTY’s shares have gained 17.2% compared with the industry’s growth of 1.6%. The S&P Index has risen 8.1% in the same period.

Image Source: Zacks Investment Research

Q2 EstimatesThe Zacks Consensus Estimate for second-quarter revenues is pegged at $704.5 million, indicating a decline of 2.2% from the prior-year quarter’s level. The consensus mark for earnings is pinned at $1.23 per share, indicating an improvement of 4.2% year over year.

Factors That Likely Drove Q2 PerformanceRevvity’s second-quarter results are likely to reflect continued resilience in its core Life Sciences and Diagnostics businesses, supported by improving demand trends in pharma, biotechnology and academic research. The company also benefits from ongoing operational efficiency initiatives. On its first-quarter earnings call, management had indicated that spending patterns among biopharma customers showed early signs of recovery during the first quarter.

The company recorded low-single-digit organic growth from the customer group, marking the strongest performance since the first half of 2023. Academic and government demand also improved, including positive U.S. growth for the first time since mid-2023. These trends are likely to have continued in the second quarter. However, uncertainty remains due to the evolving policy environment.

The Life Sciences segment results are likely to reflect steady growth supported by improving reagent demand, mid-single-digit instrument growth and continued momentum in the Signals software business. Recently launched AI-focused platforms, including Xynthetica and BioDesign, are expected to have strengthened customer engagement. The increasing adoption of high-content screening instruments, driven by GLP-1 research, organ-on-chip applications and AI-enabled drug discovery, should have provided additional support. Despite continued strength in SaaS annual recurring revenues and customer pipelines, software revenues might have been hurt due to difficult year-over-year comparisons.

The Diagnostics segment is expected to have remained the major growth driver. Reproductive Health should have continued benefiting from healthy demand for newborn screening, additional assay adoption and sustained contributions from the Genomics England partnership. The Immunodiagnostics business likely maintained stable performance in the second quarter, while persistent pricing and policy headwinds in China continued to weigh on results ahead of the planned divestiture.

While Revvity’s cost-reduction initiatives likely supported second-quarter margins, management expects their impact to become more pronounced in the second half of the year. The company is also expected to have benefited from favorable operating leverage, productivity initiatives and disciplined cost management.

While tariffs and foreign exchange remain headwinds, management continues to expect operating margin improvement through the year as restructuring actions are completed. Consequently, earnings are likely to have been supported by improving execution, stronger business mix and expanding margins despite lingering macroeconomic uncertainties.

What the Zacks Model UnveilsOur proven model does not conclusively predict an earnings beat for Revvity this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.

Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00% for RVTY. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.

Zacks Rank: The company carries a Zacks Rank #3 at present.

Stocks to ConsiderHere are some stocks worth considering from the broader medical sector, as these have the right combination of elements to post an earnings beat this reporting cycle.

Cardinal Health (CAH - Free Report) has an Earnings ESP of +1.24% and a Zacks Rank #2 at present. The company is set to release fourth-quarter fiscal 2026 results on Aug. 11. You can see the complete list of today’s Zacks #1 Rankstocks here.

CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%. The Zacks Consensus Estimate for CAH’s fourth-quarter EPS indicates an improvement of 16.4% from the year-ago reported figure.

Cencora (COR - Free Report) has an Earnings ESP of +1.49% and a Zacks Rank of 2 at present. The company is scheduled to release third-quarter fiscal 2026 results on Aug. 5.

COR’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 1.59%. The Zacks Consensus Estimate for COR’s fiscal third-quarter EPS implies an improvement of 9.3% from the year-ago reported figure.

Agilent Technologies (A - Free Report) has an Earnings ESP of +1.02% and a Zacks Rank #2 at present.

A’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 1.61%. The Zacks Consensus Estimate for A’s third-quarter fiscal 2026 EPS calls for an improvement of 8% from the year-ago reported figure.

Key Takeaways TER topped $1.3 billion in Q2 2026 revenues as Semi Test exceeded $1 billion for the second straight quarter. TER's SOC compute revenues rose nearly 600% year over year, fueled by AI-driven demand for advanced chips. Teradyne posted record memory test revenues of $212 million and expects Q3 revenues of $1.20-$1.30 billion. Teradyne (TER - Free Report) is benefiting from a powerful surge in its semiconductor test segment, fueled by the global build-out of AI data centers and the resulting demand for advanced compute and memory technologies. In the second quarter of 2026, Teradyne reported record revenues exceeding $1.3 billion, more than doubling year over year.

The Semi Test group, which includes System-on-Chip (SOC), memory, and storage test, was a standout performer, clearing the $1 billion mark for the second consecutive quarter. SOC revenues alone reached $843 million, with compute products heavily tied to AI making up 70% of that and growing nearly 600% year over year. This growth is directly linked to the proliferation of AI applications, which are driving increased investment in wafer fabrication and advanced packaging technologies.

Teradyne’s leadership in both SOC and memory test solutions positions it to capture a significant share of this expanding market. The company’s Magnum testers are well-suited for high-bandwidth memory (HBM) and DRAM, which are seeing robust demand due to AI and data center expansion.

In the second quarter of 2026, compute revenues within SOC grew nearly 600% year over year, and memory test revenues hit a record $212 million, driven by HBM, DRAM and renewed demand for NAND. The company is also making strategic moves in networking and optical test, acquiring Quantifi Photonics and developing new solutions for emerging technologies like co-packaged optics, which is expected to be a $300-$700 million market by 2028.

Teradyne’s strong performance in the semiconductor test segment is underpinned by secular growth drivers in AI, data centers and advanced packaging. For the third quarter of 2026, Teradyne expects revenues in the range of $1.20-$1.30 billion.

Teradyne Suffers From Stiff CompetitionTeradyne is facing stiff competition from companies such as Advantest Corporation (ATEYY - Free Report) and Cohu (COHU - Free Report) . Both Advantest and Cohu are expanding their footprint in the semiconductor test market.

In July 2026, Advantest expanded its SiConic ecosystem with a new Design-for-Test (DFT) Engineering environment, enabling engineers to develop, debug, validate and optimize production-ready test content before deployment to manufacturing. The solution aligns bench workflows with the V93000 platform, accelerating DFT development, improving collaboration and reducing reliance on production automated test equipment.

Cohu received approximately $5 million in multiple orders for its Diamond X platform from a leading semiconductor manufacturer. The systems will support testing of next-generation GaN power devices for AI data centers, strengthening Cohu’s position in AI infrastructure and high-efficiency power semiconductor testing.

TER’s Share Price Performance, Valuation and EstimatesTeradyne shares have surged 65% in the year-to-date period, outperforming the Zacks Computer & Technology sector’s growth of 8.9% and the Zacks Electronics - Miscellaneous Products increase of 39.2%.

TER Stock Performance
Image Source: Zacks Investment Research

TER stock is trading at a premium with a forward 12-month Price/Sales of 9.9X compared with the Electronics - Miscellaneous Products industry’s 8.31X. TER has a Value Score of D.

TER Valuation
Image Source: Zacks Investment Research

The Zacks Consensus Estimate for 2026 earnings is pegged at $7.20 per share, which has been unchanged over the past 30 days. This suggests 81.82% year-over-year growth.

Teradyne currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Key Takeaways Symbotic's fiscal Q3 revenues are expected to rise 20.7% year over year to $714.76 million. A $22.7 billion backlog and its conversion are likely to support Symbotic's fiscal Q3 revenues.High R&D and SG&A costs may pressure margins, while Fox Robotics could improve efficiency. Symbotic Inc. (SYM - Free Report) is set to report third-quarter fiscal 2026 results on Aug. 05, after market close.

The Zacks Consensus Estimate for revenues in the to-be-reported quarter is pegged at $714.76 million, indicating 20.7% year-over-year growth. The consensus estimate for earnings is pinned at 12 cents per share, remaining stable over the past 60 days and indicating a 340% surge from the year-ago quarter’s actual.

Image Source: Zacks Investment Research

SYM’s earnings surprise history is impressive. In the four trailing quarters, its earnings surpassed the Zacks Consensus Estimate thrice and missed on the other occasion. The average beat is 279.9%.

Q3 Earnings Whispers for SYM StockOur proven model does not predict an earnings beat for SYM this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. This is not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

SYM has an Earnings ESP of 0.00% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Factors Shaping SYM’s Q3 ResultsIn the second quarter of fiscal 2026, Symbotic reported a backlog of $22.7 billion. We expect backlog to have been high in the fiscal third quarter as well. SYM’s top-line performance in the fiscal third quarter is likely to have been driven by the conversion of this significant backlog.

For the third quarter of fiscal 2026, Symbotic expects revenues of $700 million to $720 million, and adjusted EBITDA of $80 million to $85 million. Free cash flow is also expected to be strong in the fiscal third quarter.

SYM’s overdependence on Walmart (WMT - Free Report) raises concerns. The partnership with Walmart, SYM’s largest customer, accounts for a significant portion of its revenues, which is likely to have been the case in the fiscal third quarter as well. In January 2025, Symbotic completed the acquisition of Walmart’s advanced systems and robotics business. High costs are also likely to have pressured margins and bottom-line performance.

Overall operating costs are likely to have escalated due to elevated research and development costs and selling, general and administrative expenses. The company has been investing heavily to maintain a technological edge and scale its operations, which in turn has pushed costs up.  

However, the acquisition of Fox Robotics earlier this year, which enhances SYM’s strategy of utilizing its software to orchestrate robots across the goods supply chain from the warehouse to the individual customer, is likely to have boosted operational efficiency.

SYM’s Price PerformanceSYM’s shares have declined more than 31% over the past three months, underperforming its industry and fellow industry participant MediaAlpha (MAX - Free Report) . Another industry player, Coherent Corp. (COHR - Free Report) , has performed worse than Symbotic over the same time frame. While MediaAlpha has gained in excess of 51%, Coherent’s shares have declined in excess of 32%.

3-Month Price ComparisonImage Source: Zacks Investment Research

For the quarter ended June 2026, Cullen/Frost Bankers (CFR - Free Report) reported revenue of $598.35 million, up 5.4% over the same period last year. EPS came in at $2.70, compared to $2.39 in the year-ago quarter.

The reported revenue represents a surprise of +0.71% over the Zacks Consensus Estimate of $594.16 million. With the consensus EPS estimate being $2.53, the EPS surprise was +6.72%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Cullen/Frost performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Net charge-offs annualized as a percentage of average loans: 0.2% compared to the 0.2% average estimate based on three analysts.Total earning assets and average rate earned - Average balance: $49.08 billion versus $49.17 billion estimated by three analysts on average.Net Interest Margin (FTE): 3.8% versus the three-analyst average estimate of 3.8%.Non-accrual loans: $112.72 million versus the two-analyst average estimate of $69.78 million.Book value per common share at end of quarter: $72.04 versus $71.60 estimated by two analysts on average.Total Non-Interest Income: $128.28 million versus $127.35 million estimated by three analysts on average.Net Interest Income (FTE): $470.07 million versus $466.81 million estimated by three analysts on average.Service charges on deposit accounts: $34.18 million versus the two-analyst average estimate of $32.23 million.Net Interest Income: $447.73 million versus the two-analyst average estimate of $445.11 million.Insurance commissions and fees: $14.17 million versus $15.14 million estimated by two analysts on average.Trust and investment management fees: $47.64 million compared to the $46.15 million average estimate based on two analysts.Other charges, commissions and fees: $13.79 million versus the two-analyst average estimate of $14.03 million.View all Key Company Metrics for Cullen/Frost here>>>

Shares of Cullen/Frost have returned +7.2% over the past month versus the Zacks S&P 500 composite's -1.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Key Takeaways MUSA is set to report Q2 2026 earnings on Aug. 5, with EPS estimated at $9.40 and revenues at $5.9 billion.MUSA earnings beat estimates in each of the past four quarters, with an average surprise of 16.56%.MUSA's higher merchandise sales may lift revenues, while rising operating costs could pressure earnings. Murphy USA Inc. (MUSA - Free Report) is set to report second-quarter 2026 earnings on Aug. 5. The Zacks Consensus Estimate for earnings is pegged at $9.40 per share and the same for revenues is pinned at $5.90 billion.

Let us delve into the factors that might have influenced MUSA’s performance in the to-be-reported quarter. Before that, it is worth taking a look at the company’s performance in the last reported quarter.

Highlights of MUSA’s Q1 Earnings & Surprise HistoryIn the last reported quarter, the motor fuel retailer posted earnings of $7.28 per share, beating the Zacks Consensus Estimate of $5.37 by 35.6%. This strong performance was primarily driven by a more favorable refined products environment and solid execution, with total fuel contribution of 35 cents per gallon and total retail fuel volumes increasing 2.1% year over year. Moreover, total operating revenues beat the consensus estimate of $4.7 billion by 3.9%.

MUSA’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 16.56%.

This is depicted in the graph below: 

Trend in MUSA’s Estimate RevisionThe Zacks Consensus Estimate for second-quarter 2026 earnings has remained unchanged in the past seven days. The estimated figure indicates a 27.72% year-over-year increase. Additionally, the Zacks Consensus Estimate for revenues implies a 17.91% increase from the year-ago period.

Factors to Consider Ahead of MUSA’s Q2 ReleaseMurphy USA operates a chain of retail fuel stations and convenience stores across the United States. The company generates most of its revenues by selling fuel, tobacco products, snacks, beverages and other everyday convenience items.

MUSA’s total revenues are likely to have increased in the quarter to be reported. The Zacks Consensus Estimate for second-quarter revenues is pegged above the year-ago quarter's level. This increase is expected to have been driven by higher merchandise sales, with merchandise revenues projected to rise 3.7% year over year.

On the other hand, the increase in MUSA's costs is expected to have dented its bottom line. MUSA’s total operating expenses are projected to reach $4.81 billion in the second quarter, which is 0.6% up from the year-ago quarter’s level. Based on our model estimates, we expect the company's cost base to have increased year over year, with Merchandise Cost of Goods Sold projected to rise 3.9%, Selling, General and Administrative expenses 20.9%, Store and Other Operating Expenses 4.6%, and Depreciation and Amortization 9.2%.

What Does Our Model Say?The proven Zacks model does not conclusively show an earnings beat for Murphy USA this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. However, that is not the case here.

Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, for this company is -2.61%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: MUSA currently carries a Zacks Rank #3.

Stocks to ConsiderHere are some firms that you may want to consider, as these have the right combination of elements to post an earnings beat.

Ryman Hospitality Properties (RHP - Free Report) has an Earnings ESP of +1.26% and a Zacks Rank #2. The firm is scheduled to release earnings on Aug. 6, 2026. You can see the complete list of today’s Zacks #1 Rank stocks here.

Ryman Hospitality Properties is a real estate investment trust that owns a large group of convention-oriented hotels and entertainment assets. This includes the Grand Ole Opry, generating revenues from hospitality, entertainment and related businesses. Ryman Hospitality has a trailing four-quarter average earnings surprise of 6.44%.

Somnigroup International Inc. (SGI - Free Report) has an Earnings ESP of +2.02% and a Zacks Rank #2. The firm is scheduled to release earnings on Aug. 6, 2026.

Somnigroup is a global bedding company that designs, manufactures and sells mattresses, adjustable bases and sleep-related products through a portfolio of well-known brands. The company has a trailing four-quarter average earnings surprise of 4.8%.

Sweetgreen (SG - Free Report) has an Earnings ESP of +11.54% and a Zacks Rank #2. The firm is scheduled to release earnings on Aug. 6, 2026.

Sweetgreen is a fast-casual restaurant chain that serves customizable salads, warm bowls and protein plates. The company has a strong focus on digital ordering and fresh, locally sourced ingredients. Sweetgreen is valued at approximately $755.74 million.

These 3 Stocks Just Graduated to the MSCI World IndexFTAI Aviation NASDAQ: FTAI reported second-quarter adjusted EBITDA of $291.4 million as its Aerospace Products business expanded production and market share, while the company continued shifting its aviation leasing operations toward a more asset-light strategic-capital model.

Chief Executive Officer Joe Adams said the company operates across Aerospace Products, Asset Management and Power, each centered on its aftermarket turbine-performance capabilities. He said all three businesses made progress during the quarter, including increased module production, the launch of a new investment vehicle and a major initial order for its power-generation offering.

Get FTAI Aviation alerts:

3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher“Our market share grew from 12%-14% this quarter,” Adams said, attributing the increase to production capacity, parts procurement strategies and customer adoption of its maintenance, repair and exchange offerings.

Aerospace Products Growth and Capacity Expansion President David Moreno said Aerospace Products revenue increased 78% year over year and 18% sequentially. Segment adjusted EBITDA reached $249.7 million, up 51% from a year earlier and 12% from the first quarter, with a 29% EBITDA margin.

Buy the Dip on 3 Overlooked Names With Major PotentialFTAI refurbished 296 CFM56 modules during the quarter across four facilities, a 61% increase from the second quarter of 2025. First-half production totaled 566 modules, ahead of the company’s midyear target. The company raised its 2026 module-production outlook to 1,200 modules from 1,050 previously.

Management said the market for CFM56 engines remains supply-constrained rather than demand-constrained. FTAI is directing a growing share of module output to third-party customers rather than its own aviation leasing fleet, a move intended to support customer relationships and its asset-light balance-sheet strategy.

Moreno said the shift and a greater mix of heavy engine shop visits are expected to affect near-term margins. In response to an analyst question, Adams said FTAI expects Aerospace Products margins to remain around 30% over the next one to two years as the company prioritizes market share and larger customer programs.

The company also announced maintenance-network expansion through partnerships with GMF AeroAsia in Jakarta, Indonesia, and EgyptAir in Cairo. The Jakarta facility has CFM56-5B and CFM56-7B heavy-repair capabilities, an engine test cell and more than 200 technicians, according to Moreno. The Cairo operation has a test cell and is currently focused on the CFM56-7B.

Other planned additions include a CFM56 and LEAP engine test cell at FTAI’s Rome quick-turn facility and a 113,000-square-foot Lisbon facility. FTAI aims to expand Lisbon production capacity to more than 300 modules annually. Management said the LEAP test-cell investment is part of a broader plan to enter the next-generation engine maintenance market as that platform matures.

Leasing Transition and Strategic Capital FTAI’s aviation leasing segment generated $88.2 million of EBITDA in the second quarter, including $5 million of insurance recoveries, $48 million from balance-sheet leasing and gains on sale, and $35 million from 2025 special-purpose vehicle management fees and co-investment returns.

Management reduced its 2026 aviation leasing EBITDA outlook to $475 million, citing the deliberate allocation of module production to third-party Aerospace Products customers and reduced reinvestment in the company’s on-balance-sheet leasing fleet. It reaffirmed Aerospace Products EBITDA guidance of $1.05 billion for 2026.

The 2025 SPV is fully committed, with more than 300 aircraft closed or under letters of intent, Moreno said. The vehicle made its first regular quarterly distribution on June 30. Its first asset-backed securities issuance, called MRE 2026, included $612 million of bonds and supported a special distribution to investors in July.

FTAI also launched its 2026 SPV, which is actively making aircraft acquisition commitments. The company plans to maintain a 15% co-investment commitment in the vehicle. Chief Financial Officer Nicholas McAleese said the company expects Strategic Capital income to comprise the majority of aviation leasing earnings by the fourth quarter, and that financial reporting could eventually reflect the company’s three stated businesses: Aerospace Products, Power and Strategic Capital.

FTAI ended the quarter with leverage of 2.7 times, within its 2.5-times to 3-times target range. During the quarter, it redeemed $105 million of 8.25% Series C preferred shares at par and received a Moody’s rating upgrade to Ba1.

Power Business Secures Initial Hyperscaler Order FTAI Power’s joint venture with Jereh Group, J&F Power Systems, signed a five-year master supply agreement with a U.S. hyperscaler. The agreement included an initial purchase order valued at $1.465 billion for 2027 Mod-1 deliveries.

Moreno said the agreement includes a significant advance payment and milestone-based payments tied to production, testing and commissioning, which he said reduces the working-capital investment needed for the production ramp. The master agreement allows the customer to issue additional orders without renegotiating terms.

The company remains on track for a commercial launch in the fourth quarter, though management said it is prudent to expect Power deliveries in 2027. The company is testing a Mod-1 unit in Miami after completing most initial testing in Montreal, and Moreno said performance has been “exceptional.”

FTAI expects 2027 total business-segment EBITDA of $2.3 billion, comprising $1.4 billion from Aerospace Products, $450 million from aviation leasing and $450 million from Power. Adams said the $450 million Power outlook is a conservative starting point based on less than 100 units, despite the company targeting more than 100 Mod-1 units for 2027. Management described a potential Power EBITDA range of $450 million to $750 million for 2027 as additional customer contracts are pursued.

Cash Flow Outlook and Dividend Increase FTAI generated $255 million of adjusted free cash flow in the first half, including the final $95 million capital call under its 2025 Strategic Capital equity commitment. The company maintained its target of approximately $1.2 billion of adjusted free cash flow before new growth initiatives for 2026.

However, after accelerating its Mod-1 production build-out by $150 million and accounting for financing related to the 2026 SPV, FTAI updated total 2026 adjusted free cash flow guidance to $878 million from $915 million.

The company increased its quarterly dividend to $0.50 per share from $0.45 per share. The dividend is scheduled to be paid Aug. 24 to shareholders of record as of Aug. 12. Adams said the increase marked FTAI’s fourth consecutive quarterly dividend increase and its 60th consecutive dividend since inception.

About FTAI Aviation (NASDAQ:FTAI)FTAI Aviation NASDAQ: FTAI is a commercial aircraft leasing company that acquires, manages and leases wide-body jet aircraft to airlines globally. The company's portfolio is focused on modern, fuel-efficient Boeing models, including the 767, 777 and 787 families, which are deployed under long-term operating leases. By concentrating on in-demand wide-body assets, FTAI Aviation seeks to deliver stable cash flows through lease rentals and maintenance reserve collections while providing airlines with flexible fleet solutions.

In addition to lease origination, FTAI Aviation offers end-to-end asset management services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in FTAI Aviation Right Now?Before you consider FTAI Aviation, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and FTAI Aviation wasn't on the list.

While FTAI Aviation currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Meta Wants AI To Become Instagram’s Third Content FeedToday, Instagram primarily surfaces content from two places: people users follow and creators they may not. Zuckerberg said AI is about to add an entirely new category.

“There are already two large sets of content to draw from — first from your friends and the people you follow, and second from creators that you don’t follow — but now there is going to be a whole new and nearly infinite universe of personalized content,” Zuckerberg said.

He said Meta’s newly launched Muse Image and Muse Video models will power that shift by generating highly personalized content tailored to individual users.

“This is going to make our services a lot more useful and engaging for people,” Zuckerberg added.

AI Is Already Reshaping InstagramMeta’s AI push is already producing measurable results across Instagram and Facebook.

The company said large language models are improving recommendation systems by developing a deeper understanding of both content and user intent, allowing Meta to surface more relevant posts and videos. On Instagram, global time spent grew at a double-digit rate during the quarter, driven largely by improvements to Feed and Reels recommendations.

Susan Li, Meta’s chief financial officer, also revealed that every public Reels and Feed post on Instagram is now automatically processed through a large language model that analyzes everything from topics to tone before feeding those signals into recommendation and ranking systems.

The company also rolled out its largest-ever Reels ranking upgrade, which drove a 15-basis-point increase in Instagram sessions. Meanwhile, more than half of all recommended content in Instagram Feed is now less than one day old—more than double the level seen a year ago.

Why It Matters For InvestorsMeta has spent years relying on creators and user-generated content to drive engagement. Zuckerberg’s latest comments suggest the company now sees AI-generated content as another long-term growth engine.

If AI can continuously generate personalized images, videos and other media that users find engaging, it could significantly expand the amount of content available on Instagram while keeping people on the platform longer—creating more opportunities to serve advertisements.

The strategy also extends beyond content recommendations. Zuckerberg said AI is already improving ad targeting, creative tools and business performance, reinforcing Meta’s broader view that artificial intelligence will become a core driver of future engagement and monetization across its apps.

Image via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

By You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Meta CEO Mark Zuckerberg. Bloomberg/Getty Images Meta has more than a quarter trillion dollars in future lease obligations — largely tied to AI data centers — as the tech giant races to build out its artificial intelligence infrastructure, a new regulatory filing shows.

In its quarterly securities filing released a day after its earnings report, Meta said it had approximately $278.99 billion in operating and finance leases that have not yet begun and were not yet included on its balance sheet.

The lease agreements cover "data centers, colocations, and certain network infrastructure" and were scheduled to begin between the remainder of the year through 2036, Meta said in the filing. The lease terms range from more than one year to 30 years.

The nearly $279 billion figure represents a roughly 53% jump from the $182.88 billion in future lease obligations Meta reported in its first-quarter filings three months earlier.

Meta said in its latest securities filing that in July, after the quarter ended, it entered into additional data center leases with commitments of about $68 billion. Those leases are expected to begin in 2027 and 2028 with lease terms of 18 to 20 years, the company said.

The disclosures offer another glimpse into the extraordinary scale of Meta's AI infrastructure push.

Earlier this month, the owner of Facebook and Instagram announced plans to expand what was already expected to be its largest AI data center. Meta said that the Louisiana data center, known as Hyperion, will grow to 5 gigawatts of compute capacity, bringing the project's anticipated cost to more than $50 billion.

On Meta's second-quarter earnings call Wednesday, CEO Mark Zuckerberg said a "significant portion" of the company's computing capacity will be used to train its AI models, power AI agents, and support its core business. Zuckerberg added that Meta also expects to "grow a large business serving large customers as well."

Separate from its future lease obligations, Meta reported $349.31 billion in non-cancelable contractual commitments comprising both short-term and long-term arrangements.

"These commitments mostly relate to third-party cloud capacity arrangements and investments in servers and network infrastructure, data centers, and consumer hardware products in Reality Labs, with approximately $53.52 billion and $81.65 billion due in 2026 and 2027, respectively," Meta said in its filing.

Meta also said it has contingent obligations to purchase up to $14.72 billion of cloud capacity over the next five years. Those commitments "may be reduced if the cloud service provider is able to sell such capacity to other customers," Meta said.

Read next

Natalie Musumeci You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Natalie is a senior reporter on Business Insider's Business News team.She was previously on BI's Legal Affairs team where she covered major cases out of state and federal court, as well as bankruptcy. Her coverage often focused on stories at the intersection of law, business, politics and technology. Natalie has covered Donald Trump’s criminal and civil cases, the wave of lawsuits against the second Trump administration, the indictment and criminal trial of Sean “Diddy” Combs, the shooting death of UnitedHealthcare CEO Brian Thompson, and the legal battles facing Elon Musk and his companies. Natalie came to Business Insider in June 2021 as a breaking news reporter, focusing on the most interesting angles around the trending news of the day. Natalie largely drove BI’s coverage around the fatal “Rust” shooting involving Alec Baldwin and the disappearance and murder of Gabby Petito.Prior to joining BI, Natalie worked for the New York Post, the New York Daily News, and The Brooklyn Paper. She has an extensive background covering crime and courts. During her more than 12-year journalism career, she did a stint covering the police beat out of the headquarters for the New York Police Department. Natalie, a Brooklyn native, graduated from Brooklyn College in 2012 with a journalism degree. Popular articles

Walmart and Amazon face legal trouble for using a points system to track and fire employees over absences: lawyersCelebrities who partied with Diddy may want to contact their lawyersAn unchecked AI could usher in a new dark ageAt Diddy's A-list 'white parties,' naked women were a staple — but that didn't seem to raise eyebrows at the timeThe illegal maneuvers the rich use to get richerOwner of ship that crashed into Baltimore bridge will likely try to invoke 1851 law used to cap damages after Titanic disaster AI Data Centers Meta More Mark Zuckerberg

After a 30% drop in less than a month, it’s fair to say that Wall Street is more divided on Tesla Inc. NASDAQ: TSLA than it has been in years. The company's latest earnings report, released last week, delivered a jarring split between record headline revenue and a sharp deterioration in profitability, and the market has been trying to make sense of it in the days since.

Tesla Today

$305.24 +6.92 (+2.32%)

As of 12:47 PM Eastern

This is a fair market value price provided by Massive. Learn more.

52-Week Range$297.38▼

$498.83P/E Ratio282.67

Price Target$402.24

Out of that confusion, two starkly different visions of Tesla's future have emerged. One camp sees a core business whose margins are collapsing under the weight of enormous artificial intelligence spending, and is heading for the exit.

Get Tesla alerts:

The other can look beyond the quarter and toward a potential merger with SpaceX NASDAQ: SPCX that could reshape the entire company.

Which of these two paths the stock ultimately follows may matter far more than any single line in the earnings report.

Path #1: A Core Business That’s Under Severe PressureThe bearish case is grounded in what the numbers actually showed. Yes, headline revenue grew strongly year-over-year, but operating margin collapsed more than 60% from where it was a year earlier while free cash flow turned negative. Earnings per share missed expectations as capital spending surged.

Dig beneath the headline numbers, and the picture looks starker still. A large chunk of Tesla's reported net income came from a one-off gain on its stake in SpaceX rather than from selling cars or storing energy. Strip that out, along with fading regulatory credit income, and the underlying profitability shrinks dramatically. For a company still valued as one of the most expensive mega-cap stocks in the market, that’s an uncomfortable place to be.

The bigger concern is that the spending shows no sign of slowing. Tesla's capital expenditure plans have ballooned to enormous levels, funding everything from its Optimus robots and Cybercabs to new factories and fresh AI initiatives. None of these have a clear near-term path to profitability, however, making Tesla, in the eyes of the bears, a stock best left alone.

Path #2: The SpaceX CardThe bulls, meanwhile, are focused on something else entirely. On the earnings call, CEO Elon Musk acknowledged the growing overlap between Tesla and SpaceX, particularly around their shared chip ambitions. However, he was careful not to confirm any formal merger discussions.

Given there had already been plenty of talk around the possibility of a merger, his comments were enough to send speculation into overdrive, with Deepwater Asset Management's Gene Munster raising the odds of an eventual merger combination to 90%.

The vision behind a deal is undeniably ambitious. Proponents describe a business that would knit together SpaceX's satellite connectivity, Tesla's real-world AI, and orbital computing into a single vertically integrated AI ecosystem.

RBC Capital Markets analyst Tom Narayan has gone as far as to model specific deal terms, arguing that a combination at a hypothetical $480 per Tesla share, a premium of more than 60% to the current price, would leave existing shareholders owning more than half of a combined entity worth trillions.

If that vision were to come to pass, then the margin questions hanging over Tesla’s car business today would end up looking like a footnote.

Why the Merger Thesis Is Still FragileThere is a significant catch, however. Far from being a rock-solid backstop, SpaceX's own valuation has been anything but stable. Its shares have fallen by around 40% from their June peak, as its pre-IPO hype evaporates and the company suffers from the same AI spending fears that have been hitting tech valuations.

There is also the simple fact that a future combination would merge two intensely capital-hungry businesses rather than pairing a cash generator with a growth project. SpaceX may boast stronger margins than Tesla in places, but it remains deeply unprofitable and is burning through cash on its own huge investment cycle. Far from being an antidote to Tesla’s woes, it could be a poisoned chalice.

Which Path Is Tesla On?Based on the stock’s recent price action at least, it’s hard not to feel that Tesla’s near-term path belongs firmly to the first camp. The dramatic margin compression, the negative free cash flow, and the enormous spending plans are already reported facts, sitting in black and white in the latest earnings report.

The SpaceX merger, by contrast, remains speculative, with no formal process announced and Musk's own comments carefully hedged. For now, the SpaceX play should best be treated as a potential upside catalyst layered on top of a Tesla comeback story that has yet to materialize.

Should You Invest $1,000 in Tesla Right Now?Before you consider Tesla, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tesla wasn't on the list.

While Tesla currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Coca-Cola (KO -1.30%) wowed the markets with its latest earnings update, demonstrating why it's a powerhouse stock and one of Warren Buffett's favorites. Despite what management acknowledged as a challenging operating environment, it reported a 6% increase in organic revenue and comparable operating margin of 35.6%, up 34.7% from last year.

The stock is clearly an excellent defensive play, as it has been for decades. That's underpinned by its stellar dividend. Here's how much a $25,000 investment pays annually in passive income.

Image source: Getty Images.

Coca-Cola is a Dividend King, which means that it has raised its payout annually for at least 50 years consecutively. It's a designation that implies rock-solid reliability, and Coke has one of the longest track records at 64 years in a row. As the recent results confirm, loyal fans buy it under nearly all conditions, which is why it's so reliable.

Historically, the dividend yields around 3%, but since yield moves inversely with the stock price, and Coca-Cola stock has been hitting it out of the park, the yield today is 2.4%.

Today's Change

(

-1.30

%) $

-1.16

Current Price

$

87.92

As of the latest increase in February, Coke pays $2.12 per share in annual dividends. At the current price, $25,000 gets you 283 shares, and you would get $600 annually from your investment.

That's not enough for retirement, but it will grow every year. It also highlights the importance of saving early, so you have enough to invest for passive income you can retire on.

Jennifer Saibil has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.